1
|
Nambo M, Nishiwaki-Ohkawa T, Ito A, Ariki ZT, Ito Y, Kato Y, Yar M, Yim JCH, Kim E, Sharkey E, Kano K, Mishiro-Sato E, Okimura K, Maruyama M, Ota W, Furukawa Y, Nakayama T, Kobayashi M, Horio F, Sato A, Crudden CM, Yoshimura T. Synthesis and preclinical testing of a selective beta-subtype agonist of thyroid hormone receptor ZTA-261. COMMUNICATIONS MEDICINE 2024; 4:152. [PMID: 39107484 PMCID: PMC11303563 DOI: 10.1038/s43856-024-00574-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Accepted: 07/04/2024] [Indexed: 08/10/2024] Open
Abstract
BACKGROUND Thyroid hormones (TH) regulate the basal metabolic rate through their receptors THRα and THRβ. TH activates lipid metabolism via THRβ, however, an excess amount of TH can lead to tachycardia, bone loss, and muscle wasting through THRα. In recent years, TH analogs that selectively bind to THRβ have gained attention as new agents for treating dyslipidemia and obesity, which continue to pose major challenges to public health worldwide. METHODS We developed a TH analog, ZTA-261, by modifying the existing THRβ-selective agonists GC-1 and GC-24. To determine the THRβ-selectivity of ZTA-261, an in vitro radiolabeled TH displacement assay was conducted. ZTA-261 was intraperitoneally injected into a mouse model of high-fat diet-induced obesity, and its effectiveness in reducing body weight and visceral fat, and improving lipid metabolism was assessed. In addition, its toxicity in the liver, heart, and bone was evaluated. RESULTS ZTA-261 is more selective towards THRβ than GC-1. Although ZTA-261 is less effective in reducing body weight and visceral fat than GC-1, it is as effective as GC-1 in reducing the levels of serum and liver lipids. These effects are mediated by the same pathway as that of T3, a natural TH, as evidenced by similar changes in the expression of TH-induced and lipid metabolism-related genes. The bone, cardiac, and hepatotoxicity of ZTA-261 are significantly lower than those of GC-1. CONCLUSIONS ZTA-261, a highly selective and less toxic THRβ agonist, has the potential to be used as a drug for treating diseases related to lipid metabolism.
Collapse
Affiliation(s)
- Masakazu Nambo
- Institute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan.
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan.
| | - Taeko Nishiwaki-Ohkawa
- Institute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan.
- Laboratory of Animal Integrative Physiology, Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan.
| | - Akihiro Ito
- Laboratory of Animal Integrative Physiology, Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan
| | - Zachary T Ariki
- Institute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan
| | - Yuka Ito
- Laboratory of Animal Integrative Physiology, Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan
| | - Yuuki Kato
- Laboratory of Animal Integrative Physiology, Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan
| | - Muhammad Yar
- Institute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan
- Interdisciplinary Research Center in Biomedical Materials, COMSATS, University Islamabad Lahore Campus, Lahore, 54000, Pakistan
| | - Jacky C-H Yim
- Institute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan
| | - Emily Kim
- Laboratory of Animal Integrative Physiology, Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan
| | - Elizabeth Sharkey
- Laboratory of Animal Integrative Physiology, Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan
| | - Keiko Kano
- Institute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan
| | - Emi Mishiro-Sato
- Institute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan
| | - Kosuke Okimura
- Laboratory of Animal Integrative Physiology, Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan
| | - Michiyo Maruyama
- Laboratory of Animal Integrative Physiology, Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan
| | - Wataru Ota
- Laboratory of Animal Integrative Physiology, Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan
| | - Yuko Furukawa
- Institute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan
| | - Tomoya Nakayama
- Laboratory of Animal Integrative Physiology, Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan
| | - Misato Kobayashi
- Laboratory of Animal Nutrition, Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan
- Department of Nutritional Sciences, Nagoya University of Arts and Sciences, Nisshin, Aichi, 470-0196, Japan
| | - Fumihiko Horio
- Laboratory of Animal Nutrition, Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan
- Department of Life Studies and Environmental Science, Nagoya Women's University, Nagoya, 467-8610, Japan
| | - Ayato Sato
- Institute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan.
- Center for One Medicine Innovative Translational Research (COMIT), Nagoya University, Nagoya, 464-8601, Japan.
| | - Cathleen M Crudden
- Institute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan.
- Department of Chemistry, Queen's University, Chernoff Hall, Kingston, ON, K7L 3N6, Canada.
| | - Takashi Yoshimura
- Institute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan.
- Laboratory of Animal Integrative Physiology, Department of Animal Sciences, Graduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8601, Japan.
- Center for One Medicine Innovative Translational Research (COMIT), Nagoya University, Nagoya, 464-8601, Japan.
| |
Collapse
|
2
|
Dubois‐Chevalier J, Gheeraert C, Berthier A, Boulet C, Dubois V, Guille L, Fourcot M, Marot G, Gauthier K, Dubuquoy L, Staels B, Lefebvre P, Eeckhoute J. An extended transcription factor regulatory network controls hepatocyte identity. EMBO Rep 2023; 24:e57020. [PMID: 37424431 PMCID: PMC10481658 DOI: 10.15252/embr.202357020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2023] [Revised: 06/16/2023] [Accepted: 06/21/2023] [Indexed: 07/11/2023] Open
Abstract
Cell identity is specified by a core transcriptional regulatory circuitry (CoRC), typically limited to a small set of interconnected cell-specific transcription factors (TFs). By mining global hepatic TF regulons, we reveal a more complex organization of the transcriptional regulatory network controlling hepatocyte identity. We show that tight functional interconnections controlling hepatocyte identity extend to non-cell-specific TFs beyond the CoRC, which we call hepatocyte identity (Hep-ID)CONNECT TFs. Besides controlling identity effector genes, Hep-IDCONNECT TFs also engage in reciprocal transcriptional regulation with TFs of the CoRC. In homeostatic basal conditions, this translates into Hep-IDCONNECT TFs being involved in fine tuning CoRC TF expression including their rhythmic expression patterns. Moreover, a role for Hep-IDCONNECT TFs in the control of hepatocyte identity is revealed in dedifferentiated hepatocytes where Hep-IDCONNECT TFs are able to reset CoRC TF expression. This is observed upon activation of NR1H3 or THRB in hepatocarcinoma or in hepatocytes subjected to inflammation-induced loss of identity. Our study establishes that hepatocyte identity is controlled by an extended array of TFs beyond the CoRC.
Collapse
Affiliation(s)
| | - Céline Gheeraert
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011‐EGIDLilleFrance
| | - Alexandre Berthier
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011‐EGIDLilleFrance
| | - Clémence Boulet
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011‐EGIDLilleFrance
| | - Vanessa Dubois
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011‐EGIDLilleFrance
- Basic and Translational Endocrinology (BaTE), Department of Basic and Applied Medical SciencesGhent UniversityGhentBelgium
| | - Loïc Guille
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011‐EGIDLilleFrance
| | - Marie Fourcot
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 – UAR 2014 – PLBSLilleFrance
| | - Guillemette Marot
- Univ. Lille, Inria, CHU Lille, ULR 2694 – METRICS: Évaluation des technologies de santé et des pratiques médicalesLilleFrance
| | - Karine Gauthier
- Institut de Génomique Fonctionnelle de Lyon (IGFL), CNRS UMR 5242, INRAE USC 1370, École Normale Supérieure de LyonLyonFrance
| | - Laurent Dubuquoy
- Univ. Lille, Inserm, CHU Lille, U1286 – INFINITE – Institute for Translational Research in InflammationLilleFrance
| | - Bart Staels
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011‐EGIDLilleFrance
| | - Philippe Lefebvre
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011‐EGIDLilleFrance
| | - Jérôme Eeckhoute
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011‐EGIDLilleFrance
| |
Collapse
|
3
|
Gillis NE, Cozzens LM, Wilson ER, Smith NM, Tomczak JA, Bolf EL, Carr FE. TRβ Agonism Induces Tumor Suppression and Enhances Drug Efficacy in Anaplastic Thyroid Cancer in Female Mice. Endocrinology 2023; 164:bqad135. [PMID: 37702560 PMCID: PMC10506733 DOI: 10.1210/endocr/bqad135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/18/2023] [Revised: 08/29/2023] [Accepted: 09/01/2023] [Indexed: 09/14/2023]
Abstract
Thyroid hormone receptor beta (TRβ) is a recognized tumor suppressor in numerous solid cancers. The molecular signaling of TRβ has been elucidated in several cancer types through re-expression models. Remarkably, the potential impact of selective activation of endogenous TRβ on tumor progression remains largely unexplored. We used cell-based and in vivo assays to evaluate the effects of the TRβ agonist sobetirome (GC-1) on a particularly aggressive and dedifferentiated cancer, anaplastic thyroid cancer (ATC). Here we report that GC-1 reduced the tumorigenic phenotype, decreased cancer stem-like cell populations, and induced redifferentiation of the ATC cell lines with different mutational backgrounds. Of note, this selective activation of TRβ amplified the effects of therapeutic agents in blunting the aggressive cell phenotype and stem cell growth. In xenograft assays, GC-1 alone inhibited tumor growth and was as effective as the kinase inhibitor, sorafenib. These results indicate that selective activation of TRβ not only induces a tumor suppression program de novo but enhances the effectiveness of anticancer agents, revealing potential novel combination therapies for ATC and other aggressive solid tumors.
Collapse
Affiliation(s)
- Noelle E Gillis
- Department of Pharmacology, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA
- University of Vermont Cancer Center, University of Vermont, Burlington, VT 05405, USA
| | - Lauren M Cozzens
- Department of Pharmacology, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA
| | - Emily R Wilson
- Department of Pharmacology, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA
| | - Noah M Smith
- Department of Pharmacology, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA
| | - Jennifer A Tomczak
- Department of Pharmacology, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA
| | - Eric L Bolf
- Department of Pharmacology, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA
- University of Vermont Cancer Center, University of Vermont, Burlington, VT 05405, USA
| | - Frances E Carr
- Department of Pharmacology, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA
- University of Vermont Cancer Center, University of Vermont, Burlington, VT 05405, USA
| |
Collapse
|
4
|
Kent NL, Atluri SC, Moritz KM, Cuffe JSM. Maternal hypothyroidism in rats impairs placental nutrient transporter expression, increases labyrinth zone size, and impairs fetal growth. Placenta 2023; 139:148-158. [PMID: 37406552 DOI: 10.1016/j.placenta.2023.06.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Revised: 06/05/2023] [Accepted: 06/14/2023] [Indexed: 07/07/2023]
Abstract
INTRODUCTION Hypothyroidism during pregnancy is associated with fetal growth restriction (FGR). FGR is commonly caused by placental insufficiency and yet the role of hypothyroidism in placental regulation of fetal growth is unknown. This study aimed to investigate the effects of maternal hypothyroidism on placental nutrient transporter expression, placental morphology, and placental metabolism. METHODS Hypothyroidism was induced in female Sprague-Dawley rats by adding methimazole (MMI) to drinking water at moderate (MOD, MMI at 0.005% w/v) and severe (SEV, MMI at 0.02% w/v) doses from one week prior to pregnancy and throughout gestation. Maternal and fetal tissues were collected on embryonic day 20 (E20). RESULTS Hypothyroidism reduced fetal weight (PTrt<0.001) despite causing fetal hyperglycaemia (PTrt = 0.016). Placental weight was not affected by hypothyroidism however placental efficiency was reduced (PTrt<0.001), as was the junctional zone (JZ):labyrinth zone (LZ) weight ratio (PTrt = 0.005). LZ glycogen content was increased (PTrt = 0.029) and while mRNA expression of glucose transporters was reduced by hypothyroidism, only GLUT1 protein expression was reduced in male LZs. Maternal hypothyroidism reduced mitochondrial content (PTrt = 0.031), particularly in SEV males relative to CON males (P = 0.004). Protein expression of Complex V (P < 0.001) and Complex III (P = 0.002) of the electron transport chain were also reduced in males. Maternal hypothyroidism reduced LZ (PTrt<0.001) and fetal plasma triglycerides (P = 0.019) while fetal free fatty acids and the expression of LZ lipid transporters was not affected. DISCUSSION Overall, maternal hypothyroidism may lead to FGR through reduced maternal T4 availability, changes to placental morphology, altered nutrient transporter expression and sex-specific effects on placental metabolism. Changes to LZ glycogen and triglyceride stores as well as mitochondrial content suggest a metabolic shift from oxidative phosphorylation to anaerobic glycolysis in males. These changes also likely impact fetal substrate availability and therefore fetal growth.
Collapse
Affiliation(s)
- Nykola L Kent
- School of Biomedical Sciences, The University of Queensland, Brisbane, QLD, Australia
| | - Sharat C Atluri
- School of Biomedical Sciences, The University of Queensland, Brisbane, QLD, Australia
| | - Karen M Moritz
- School of Biomedical Sciences, The University of Queensland, Brisbane, QLD, Australia
| | - James S M Cuffe
- School of Biomedical Sciences, The University of Queensland, Brisbane, QLD, Australia.
| |
Collapse
|
5
|
Chew NWS, Ng CH, Truong E, Noureddin M, Kowdley KV. Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update. Semin Liver Dis 2022; 42:379-400. [PMID: 35709720 DOI: 10.1055/a-1877-9656] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Nonalcoholic steatohepatitis (NASH) is a burgeoning global health crisis that mirrors the obesity pandemic. This global health crisis has stimulated active research to develop novel NASH pharmacotherapies targeting dysregulated inflammatory, cellular stress, and fibrogenetic processes that include (1) metabolic pathways to improve insulin sensitivity, de novo lipogenesis, and mitochondrial utilization of fatty acids; (2) cellular injury or inflammatory targets that reduce inflammatory cell recruitment and signaling; (3) liver-gut axis targets that influence bile acid enterohepatic circulation and signaling; and (4) antifibrotic targets. In this review, we summarize several of the therapeutic agents that have been studied in phase 2 and 3 randomized trials. In addition to reviewing novel therapeutic drugs targeting nuclear receptor pathways, liver chemokine receptors, liver lipid metabolism, lipotoxicity or cell death, and glucagon-like peptide-1 receptors, we also discuss the rationale behind the use of combination therapy and the lessons learned from unsuccessful or negative clinical trials.
Collapse
Affiliation(s)
- Nicholas W S Chew
- Department of Cardiology, National University Heart Centre, National University Hospital, Singapore, Singapore
| | - Cheng Han Ng
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
| | - Emily Truong
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California
| | - Mazen Noureddin
- Division of Digestive and Liver Diseases, Department of Medicine, Cedars-Sinai Fatty Liver Program, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California
| | - Kris V Kowdley
- Liver Institute Northwest and Elson S. Floyd College of Medicine, Washington State University, Seattle, Washington
| |
Collapse
|
6
|
Kent NL, Atluri SC, Cuffe JSM. Maternal Hypothyroidism in Rats Reduces Placental Lactogen, Lowers Insulin Levels, and Causes Glucose Intolerance. Endocrinology 2022; 163:6429715. [PMID: 34791119 DOI: 10.1210/endocr/bqab231] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/11/2021] [Indexed: 11/19/2022]
Abstract
Hypothyroidism increases the incidence of gestational diabetes mellitus (GDM) but the mechanisms responsible are unknown. This study aimed to assess the pathophysiological mechanisms by which hypothyroidism leads to glucose intolerance in pregnancy. Hypothyroidism was induced in female Sprague-Dawley rats by adding methimazole (MMI) to drinking water at moderate (MOD, MMI at 0.005% w/v) and severe (SEV, MMI at 0.02% w/v) doses from 1 week before pregnancy and throughout gestation. A nonpregnant cohort received the same dose for the same duration but were not mated. On gestational day 16 (GD16), or nonpregnant day 16 (NP16), animals were subjected to an intraperitoneal glucose tolerance test. Tissues and blood samples were collected 4 days later. Hypothyroidism induced a diabetic-like phenotype by GD16 in pregnant females only. Pregnant MOD and SEV females had reduced fasting plasma insulin, less insulin following a glucose load, and altered expression of genes involved in insulin signaling within skeletal muscle and adipose tissue. Hypothyroidism reduced rat placental lactogen concentrations, which was accompanied by reduced percentage β-cell cross-sectional area (CSA) relative to total pancreas CSA, and a reduced number of large β-cell clusters in the SEV hypothyroid group. Plasma triglycerides and free fatty acids were reduced by hypothyroidism in pregnant rats, as was the expression of genes that regulate lipid homeostasis. Hypothyroidism in pregnant rats results in a diabetic-like phenotype that is likely mediated by impaired β-cell expansion in pregnancy. This pregnancy-specific phenomenon is likely due to reduced placental lactogen secretion.
Collapse
Affiliation(s)
- Nykola Louise Kent
- School of Biomedical Sciences, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Sharat Chandra Atluri
- School of Biomedical Sciences, The University of Queensland, Brisbane, Queensland 4072, Australia
| | | |
Collapse
|
7
|
Abstract
Cholestatic and non-alcoholic fatty liver disease (NAFLD) share several key pathophysiological mechanisms which can be targeted by novel therapeutic concepts that are currently developed for both areas. Nuclear receptors (NRs) are ligand-activated transcriptional regulators of key metabolic processes including hepatic lipid and glucose metabolism, energy expenditure and bile acid (BA) homoeostasis, as well as inflammation, fibrosis and cellular proliferation. Dysregulation of these processes contributes to the pathogenesis and progression of cholestatic as well as fatty liver disease, placing NRs at the forefront of novel therapeutic approaches. This includes BA and fatty acid activated NRs such as farnesoid-X receptor (FXR) and peroxisome proliferator-activated receptors, respectively, for which high affinity therapeutic ligands targeting specific or multiple isoforms have been developed. Moreover, novel liver-specific ligands for thyroid hormone receptor beta 1 complete the spectrum of currently available NR-targeted drugs. Apart from FXR ligands, BA signalling can be targeted by mimetics of FXR-activated fibroblast growth factor 19, modulation of their enterohepatic circulation through uptake inhibitors in hepatocytes and enterocytes, as well as novel BA derivatives undergoing cholehepatic shunting (instead of enterohepatic circulation). Other therapeutic approaches more directly target inflammation and/or fibrosis as critical events of disease progression. Combination strategies synergistically targeting metabolic disturbances, inflammation and fibrosis may be ultimately necessary for successful treatment of these complex and multifactorial disorders.
Collapse
Affiliation(s)
- Michael Trauner
- Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
| | - Claudia Daniela Fuchs
- Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
8
|
Davidson CD, Gillis NE, Carr FE. Thyroid Hormone Receptor Beta as Tumor Suppressor: Untapped Potential in Treatment and Diagnostics in Solid Tumors. Cancers (Basel) 2021; 13:4254. [PMID: 34503062 PMCID: PMC8428233 DOI: 10.3390/cancers13174254] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2021] [Revised: 08/17/2021] [Accepted: 08/19/2021] [Indexed: 01/07/2023] Open
Abstract
There is compelling evidence that the nuclear receptor TRβ, a member of the thyroid hormone receptor (TR) family, is a tumor suppressor in thyroid, breast, and other solid tumors. Cell-based and animal studies reveal that the liganded TRβ induces apoptosis, reduces an aggressive phenotype, decreases stem cell populations, and slows tumor growth through modulation of a complex interplay of transcriptional networks. TRβ-driven tumor suppressive transcriptomic signatures include repression of known drivers of proliferation such as PI3K/Akt pathway, activation of novel signaling such as JAK1/STAT1, and metabolic reprogramming in both thyroid and breast cancers. The presence of TRβ is also correlated with a positive prognosis and response to therapeutics in BRCA+ and triple-negative breast cancers, respectively. Ligand activation of TRβ enhances sensitivity to chemotherapeutics. TRβ co-regulators and bromodomain-containing chromatin remodeling proteins are emergent therapeutic targets. This review considers TRβ as a potential biomolecular diagnostic and therapeutic target.
Collapse
Affiliation(s)
- Cole D. Davidson
- Department of Pharmacology, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA; (C.D.D.); (N.E.G.)
- University of Vermont Cancer Center, Burlington, VT 05401, USA
| | - Noelle E. Gillis
- Department of Pharmacology, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA; (C.D.D.); (N.E.G.)
- University of Vermont Cancer Center, Burlington, VT 05401, USA
| | - Frances E. Carr
- Department of Pharmacology, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA; (C.D.D.); (N.E.G.)
- University of Vermont Cancer Center, Burlington, VT 05401, USA
| |
Collapse
|
9
|
Hu L, Wu C. Using Single-Cell RNA-Seq Data to Trace Tissue Cells Responsive to Thyroid Hormones. Front Endocrinol (Lausanne) 2021; 12:609308. [PMID: 33716967 PMCID: PMC7943891 DOI: 10.3389/fendo.2021.609308] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Accepted: 01/13/2021] [Indexed: 11/23/2022] Open
Abstract
Thyroid hormones mediate a remarkable range of functions in many tissues and organ systems through the thyroid hormone receptors-THRA and THRB. Tissues and organs are composed of heterogeneous cells of different cell types. These different cell types have varying receptor expression abilities, which lead to variable responses in thyroid hormone regulation. The tissue-specific Thra and Thrb gene expression patterns help us understand the action of thyroid hormones at the tissue level. However, the situation becomes complicated if we wish to focus on tissues more closely to trace the responsive cells, which is a vital step in the process of understanding the molecular mechanism of diseases related to thyroid hormone regulation. Single-cell RNA sequencing technology is a powerful tool used to profile gene expression programs in individual cells. The Tabula Muris Consortium generates a single-cell transcriptomic atlas across the life span of Mus musculus that includes data from 23 tissues and organs. It provides an unprecedented opportunity to understand thyroid hormone regulation at the cell type resolution. We demonstrated the approaches that allow application of the single-cell RNA-Seq data generated by the Tabula Muris Consortium to trace responsive cells in tissues. First, employing the single-cell RNA-Seq data, we calculated the ability of different cell types to express Thra and Thrb, which direct us to the cell types sensitive to thyroid hormone regulation in tissues and organs. Next, using a cell clustering algorithm, we explored the subtypes with low Thra or Thrb expression within the different cell types and identified the potentially responsive cell subtypes. Finally, in the liver tissue treated with thyroid hormones, using the single-cell RNA-Seq data, we successfully traced the responsive cell types. We acknowledge that the computational predictions reported here need to be further validated using wet-lab experiments. However, we believe our results provide powerful information and will be beneficial for wet lab researchers.
Collapse
Affiliation(s)
- Liang Hu
- Department of Thyroid Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Chao Wu
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- *Correspondence: Chao Wu,
| |
Collapse
|
10
|
Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH). PLoS One 2020; 15:e0240338. [PMID: 33306682 PMCID: PMC7732128 DOI: 10.1371/journal.pone.0240338] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Accepted: 11/26/2020] [Indexed: 12/16/2022] Open
Abstract
Thyroid hormones are important modulators of metabolic activity in mammals and alter cholesterol and fatty acid levels through activation of the nuclear thyroid hormone receptor (THR). Currently, there are several THRβ agonists in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) that have demonstrated the potential to reduce liver fat and restore liver function. In this study, we tested three THRβ-agonism-based NASH treatment candidates, GC-1 (sobetirome), MGL-3196 (resmetirom), and VK2809, and compared their selectivity for THRβ and their ability to modulate the expression of genes specific to cholesterol and fatty acid biosynthesis and metabolism in vitro using human hepatic cells and in vivo using a rat model. Treatment with GC-1 upregulated the transcription of CPT1A in the human hepatocyte-derived Huh-7 cell line with a dose-response comparable to that of the native THR ligand, triiodothyronine (T3). VK2809A (active parent of VK2809), MGL-3196, and VK2809 were approximately 30-fold, 1,000-fold, and 2,000-fold less potent than T3, respectively. Additionally, these relative potencies were confirmed by quantification of other direct gene targets of THR, namely, ANGPTL4 and DIO1. In primary human hepatocytes, potencies were conserved for every compound except for VK2809, which showed significantly increased potency that was comparable to that of its active counterpart, VK2809A. In high-fat diet fed rats, a single dose of T3 significantly reduced total cholesterol levels and concurrently increased liver Dio1 and Me1 RNA expression. MGL-3196 treatment resulted in concentration-dependent decreases in total and low-density lipoprotein cholesterol with corresponding increases in liver gene expression, but the compound was significantly less potent than T3. In conclusion, we have implemented a strategy to rank the efficacy of THRβ agonists by quantifying changes in the transcription of genes that lead to metabolic alterations, an effect that is directly downstream of THR binding and activation.
Collapse
|
11
|
Li J, Li L, Guo D, Li S, Zeng Y, Liu C, Fu R, Huang M, Xie W. Triglyceride metabolism and angiopoietin-like proteins in lipoprotein lipase regulation. Clin Chim Acta 2020; 503:19-34. [PMID: 31923423 DOI: 10.1016/j.cca.2019.12.029] [Citation(s) in RCA: 39] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2019] [Revised: 12/31/2019] [Accepted: 12/31/2019] [Indexed: 12/21/2022]
Abstract
Hypertriglyceridemia is a risk factor for a series of diseases, such as cardiovascular disease (CVD), diabetes and nonalcoholic fatty liver disease (NAFLD). Angiopoietin-like proteins (ANGPTLs) family, especially ANGPTL3, ANGPTL4 and ANGPTL8, which regulate lipoprotein lipase (LPL) activity, play pivotal roles in triglyceride (TG) metabolism and related diseases/complications. There are many transcriptional and post-transcriptional factors that participate in physiological and pathological regulation of ANGPTLs to affect triglyceride metabolism. This review is intended to focus on the similarity and difference in the expression, structural features, regulation profile of the three ANGPTLs and inhibitory models for LPL. Description of the regulatory factors of ANGPTLs and the properties in regulating the lipid metabolism involved in the underlying mechanisms in pathological effects on diseases will provide potential therapeutic approaches for the treatment of dyslipidemia related diseases.
Collapse
Affiliation(s)
- Jing Li
- Clinical Anatomy & Reproductive Medicine Application Institute, University of South China, Hengyang 421001, Hunan, China; 2016 Class of Clinical Medicine, University of South China, Hengyang 421001, Hunan, China
| | - Liang Li
- Department of Pathophysiology, University of South China, Hengyang 421001, Hunan, China
| | - DongMing Guo
- Clinical Anatomy & Reproductive Medicine Application Institute, University of South China, Hengyang 421001, Hunan, China
| | - SuYun Li
- Clinical Anatomy & Reproductive Medicine Application Institute, University of South China, Hengyang 421001, Hunan, China
| | - YuXin Zeng
- 2018 Class of Excellent Doctor, University of South China, Hengyang 421001, Hunan, China
| | - ChuHao Liu
- Clinical Anatomy & Reproductive Medicine Application Institute, University of South China, Hengyang 421001, Hunan, China; 2016 Class of Clinical Medicine, University of South China, Hengyang 421001, Hunan, China
| | - Ru Fu
- Clinical Anatomy & Reproductive Medicine Application Institute, University of South China, Hengyang 421001, Hunan, China; 2016 Class of Clinical Medicine, University of South China, Hengyang 421001, Hunan, China
| | - MengQian Huang
- 2015 Class of Clinical Medicine, Fuxing Hospital, Capital Medical University, Beijing 100038, China.
| | - Wei Xie
- Clinical Anatomy & Reproductive Medicine Application Institute, University of South China, Hengyang 421001, Hunan, China.
| |
Collapse
|
12
|
Jakobsson T, Vedin LL, Parini P. Potential Role of Thyroid Receptor β Agonists in the Treatment of Hyperlipidemia. Drugs 2019; 77:1613-1621. [PMID: 28865063 PMCID: PMC5613055 DOI: 10.1007/s40265-017-0791-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Thyroid hormones have important effects on cellular development, growth, and metabolism and are necessary for the healthy function of almost all tissues. Hyperthyroid patients with excess thyroid hormone levels experience tachycardia, fatigue, muscle wasting, and osteoporosis. However, although high thyroid hormone levels have adverse effects, efforts have been made to harness the beneficial effects, such as reduced serum low-density lipoprotein (LDL) cholesterol levels, elevated basal metabolic rate, and weight loss. Thyroid hormones interact with nuclear thyroid hormone receptors (TRs), and cholesterol levels are reduced through TRβ, whereas extrahepatic adverse actions are primarily connected to TRα. Thus, to develop a useful compound for clinical use, efforts have been focusing on developing compounds with isomer-specific functions based on the structure of thyroid hormones, i.e., thyromimetics that are liver and/or TRβ specific. In this short review, we discuss the development of the early thyromimetics that enabled, through modern molecular techniques, the progress towards improved design of TRβ-selective thyromimetics. We also address the early promise shown in human clinical trials and the current status of these drugs and other emerging compounds.
Collapse
Affiliation(s)
- Tomas Jakobsson
- Division of Clinical Chemistry, C1:74, Department of Laboratory Medicine, Karolinska University Hospital Huddinge, 141 86, Stockholm, Sweden
| | - Lise-Lotte Vedin
- Division of Clinical Chemistry, C1:74, Department of Laboratory Medicine, Karolinska University Hospital Huddinge, 141 86, Stockholm, Sweden
| | - Paolo Parini
- Division of Clinical Chemistry, C1:74, Department of Laboratory Medicine, Karolinska University Hospital Huddinge, 141 86, Stockholm, Sweden. .,Metabolism Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden. .,Inflammation and Infection Theme, Karolinska University Hospital, Stockholm, Sweden.
| |
Collapse
|
13
|
Gautherot J, Claudel T, Cuperus F, Fuchs CD, Falguières T, Trauner M. Thyroid hormone receptor β1 stimulates ABCB4 to increase biliary phosphatidylcholine excretion in mice. J Lipid Res 2018; 59:1610-1619. [PMID: 29895698 PMCID: PMC6121935 DOI: 10.1194/jlr.m084145] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Revised: 06/12/2018] [Indexed: 12/15/2022] Open
Abstract
The ATP-binding cassette transporter ABCB4/MDR3 is critical for biliary phosphatidylcholine (PC) excretion at the canalicular membrane of hepatocytes. Defective ABCB4 gene expression and protein function result in various cholestatic liver and bile duct injuries. Thyroid hormone receptor (THR) is a major regulator of hepatic lipid metabolism; we explored its potential role in ABCB4 regulation. Thyroid hormone T3 stimulation to human hepatocyte models showed direct transcriptional activation of ABCB4 in a dose- and time-dependent manner. To determine whether THRβ1 (the main THR isoform of the liver) is involved in regulation, we tested THRβ1-specific agonists (e.g., GC-1, KB-141); these agonists resulted in greater stimulation than the native hormone. KB-141 activated hepatic ABCB44 expression in mice, which enhanced biliary PC secretion in vivo. We also identified THR response elements 6 kb upstream of the ABCB4 locus that were conserved in humans and mice. Thus, T3-via THRβ1 as a novel transcriptional activator regulates ABCB4 to increase ABCB4 protein levels at the canalicular membrane and promote PC secretion into bile. These findings may have important implications for understanding thyroid hormone function as a potential modifier of bile duct homeostasis and provide pharmacologic opportunities to improve liver function in hepatobiliary diseases caused by low ABCB4 expression.
Collapse
Affiliation(s)
- Julien Gautherot
- Hans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; and
| | - Thierry Claudel
- Hans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; and
| | - Frans Cuperus
- Hans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; and
| | - Claudia Daniela Fuchs
- Hans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; and
| | - Thomas Falguières
- INSERM & Pierre et Marie Curie University/Paris 06, UMR_S 938, Saint-Antoine Research Center, Paris, France
| | - Michael Trauner
- Hans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; and.
| |
Collapse
|
14
|
McQueen AE, Kanamaluru D, Yan K, Gray NE, Wu L, Li ML, Chang A, Hasan A, Stifler D, Koliwad SK, Wang JC. The C-terminal fibrinogen-like domain of angiopoietin-like 4 stimulates adipose tissue lipolysis and promotes energy expenditure. J Biol Chem 2017; 292:16122-16134. [PMID: 28842503 DOI: 10.1074/jbc.m117.803973] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2017] [Revised: 08/23/2017] [Indexed: 01/08/2023] Open
Abstract
Angptl4 (Angiopoietin-like 4) is a circulating protein secreted by white and brown adipose tissues and the liver. Structurally, Angptl4 contains an N-terminal coiled-coil domain (CCD) connected to a C-terminal fibrinogen-like domain (FLD) via a cleavable linker, and both full-length Angptl4 and its individual domains circulate in the bloodstream. Angptl4 inhibits extracellular lipoprotein lipase (LPL) activity and stimulates the lipolysis of triacylglycerol stored by adipocytes in the white adipose tissue (WAT). The former activity is furnished by the CCD, but the Angptl4 domain responsible for stimulating adipocyte lipolysis is unknown. We show here that the purified FLD of Angptl4 is sufficient to stimulate lipolysis in mouse primary adipocytes and that increasing circulating FLD levels in mice through adenovirus-mediated overexpression (Ad-FLD) not only induces WAT lipolysis in vivo but also reduces diet-induced obesity without affecting LPL activity. Intriguingly, reduced adiposity in Ad-FLD mice was associated with increased oxygen consumption, fat utilization, and the expression of thermogenic genes (Ucp1 and Ppargc1a) in subcutaneous WAT. Moreover, Ad-FLD mice exhibited increased glucose tolerance. Chronically enhancing WAT lipolysis could produce ectopic steatosis because of an overflow of lipids from the WAT to peripheral tissues; however, this did not occur when Ad-FLD mice were fed a high-fat diet. Rather, these mice had reductions in both circulating triacylglycerol levels and the mRNA levels of lipogenic genes in the liver and skeletal muscle. We conclude that separating the FLD from the CCD-mediated LPL-inhibitory activity of full-length Angptl4 reveals lipolytic and thermogenic properties with therapeutic relevance to obesity and diabetes.
Collapse
Affiliation(s)
- Allison E McQueen
- From the Metabolic Biology Graduate Program and.,the Department of Nutritional Sciences & Toxicology, University of California Berkeley, Berkeley, California 94720 and
| | - Deepthi Kanamaluru
- the Department of Nutritional Sciences & Toxicology, University of California Berkeley, Berkeley, California 94720 and
| | - Kimberly Yan
- the Department of Nutritional Sciences & Toxicology, University of California Berkeley, Berkeley, California 94720 and
| | - Nora E Gray
- From the Metabolic Biology Graduate Program and.,the Department of Nutritional Sciences & Toxicology, University of California Berkeley, Berkeley, California 94720 and
| | - Leslie Wu
- the Department of Nutritional Sciences & Toxicology, University of California Berkeley, Berkeley, California 94720 and
| | - Mei-Lan Li
- the Department of Nutritional Sciences & Toxicology, University of California Berkeley, Berkeley, California 94720 and
| | - Anthony Chang
- the Department of Nutritional Sciences & Toxicology, University of California Berkeley, Berkeley, California 94720 and
| | - Adeeba Hasan
- the Department of Nutritional Sciences & Toxicology, University of California Berkeley, Berkeley, California 94720 and
| | | | - Suneil K Koliwad
- the Diabetes Center and .,the Department of Medicine, University of California San Francisco, San Francisco, California 94143
| | - Jen-Chywan Wang
- From the Metabolic Biology Graduate Program and .,the Department of Nutritional Sciences & Toxicology, University of California Berkeley, Berkeley, California 94720 and
| |
Collapse
|
15
|
Shpakov AO. [Pharmacological approaches for correction of thyroid dysfunctions in diabetes mellitus]. BIOMEDIT︠S︡INSKAI︠A︡ KHIMII︠A︡ 2017; 63:219-231. [PMID: 28781255 DOI: 10.18097/pbmc20176303219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Thyroid diseases are closely associated with the development of types 1 and 2 diabetes mellitus (DM), and as a consequence, the development of effective approaches for their treatment is one of the urgent problems of endocrinology. Traditionally, thyroid hormones (TH) are used to correct functions of the thyroid system. However, they are characterized by many side effects, such as their negative effect on the cardiovascular system as well as the ability of TH to enhance insulin resistance and to disturb insulin-producing function of pancreas, exacerbating thereby diabetic pathology. Therefore, the analogues of TH, selective for certain types of TH receptors, that do not have these side effects, are being developed. The peptide and low-molecular weight regulators of thyroid-stimulating hormone receptor, which regulate the activity of the thyroid axis at the stage of TH synthesis and secretion in thyrocytes, are being created. Systemic and intranasal administration of insulin, metformin therapy and drugs with antioxidant activity are effective for the treatment of thyroid pathology in types 1 and 2 DM. In the review, the literature data and the results of own investigations on pharmacological approaches for the treatment and prevention of thyroid diseases in patients with types 1 and 2 DM are summarized and analyzed.
Collapse
Affiliation(s)
- A O Shpakov
- I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences
| |
Collapse
|
16
|
Milanesi A, Brent GA. Beam Me In: Thyroid Hormone Analog Targets Alternative Transporter in Mouse Model of X-Linked Adrenoleukodystrophy. Endocrinology 2017; 158:1116-1119. [PMID: 28609836 PMCID: PMC5460838 DOI: 10.1210/en.2017-00206] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/28/2017] [Accepted: 02/25/2017] [Indexed: 01/04/2023]
Affiliation(s)
- Anna Milanesi
- Department of Medicine, Veterans Affairs Greater Los Angeles Healthcare System, and Endocrinology Division, Departments of Medicine and Physiology, David Geffen School of Medicine at UCLA, Los Angeles, California 90073
| | - Gregory A Brent
- Department of Medicine, Veterans Affairs Greater Los Angeles Healthcare System, and Endocrinology Division, Departments of Medicine and Physiology, David Geffen School of Medicine at UCLA, Los Angeles, California 90073
| |
Collapse
|
17
|
Wang FF, Yang W, Shi YH, Le GW. Probing the structural requirements for thyroid hormone receptor inhibitory activity of sulfonylnitrophenylthiazoles (SNPTs) using 2D-QSAR and 3D-QSAR approaches. Med Chem Res 2016. [DOI: 10.1007/s00044-016-1751-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
18
|
Ligand Independent and Subtype-Selective Actions of Thyroid Hormone Receptors in Human Adipose Derived Stem Cells. PLoS One 2016; 11:e0164407. [PMID: 27732649 PMCID: PMC5061422 DOI: 10.1371/journal.pone.0164407] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2016] [Accepted: 09/23/2016] [Indexed: 12/14/2022] Open
Abstract
Thyroid hormone (TH) receptors (TRs α and β) are homologous ligand-dependent transcription factors (TFs). While the TRs display distinct actions in development, metabolic regulation and other processes, comparisons of TRα and TRβ dependent gene regulation mostly reveal similar mechanisms of action and few TR subtype specific genes. Here, we show that TRα predominates in multipotent human adipose derived stem cells (hADSC) whereas TRβ is expressed at lower levels and is upregulated during hADSC differentiation. The TRs display several unusual properties in parental hADSC. First, TRs display predominantly cytoplasmic intracellular distribution and major TRα variants TRα1 and TRα2 colocalize with mitochondria. Second, knockdown experiments reveal that endogenous TRs influence hADSC cell morphology and expression of hundreds of genes in the absence of hormone, but do not respond to exogenous TH. Third, TRα and TRβ affect hADSC in completely distinct ways; TRα regulates cell cycle associated processes while TRβ may repress aspects of differentiation. TRα splice variant specific knockdown reveals that TRα1 and TRα2 both contribute to TRα-dependent gene expression in a gene specific manner. We propose that TRs work in a non-canonical and hormone independent manner in hADSC and that prominent subtype-specific activities emerge in the context of these unusual actions.
Collapse
|
19
|
Filgueira CS, Nicolov E, Hood RL, Ballerini A, Garcia-Huidobro J, Lin JZ, Fraga D, Webb P, Sabek OM, Gaber AO, Phillips KJ, Grattoni A. Sustained zero-order delivery of GC-1 from a nanochannel membrane device alleviates metabolic syndrome. Int J Obes (Lond) 2016; 40:1776-1783. [PMID: 27460601 DOI: 10.1038/ijo.2016.129] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2016] [Revised: 06/16/2016] [Accepted: 06/25/2016] [Indexed: 12/20/2022]
Abstract
BACKGROUND/OBJECTIVES Our objective was to assess the sustained, low-dose and constant administration of the thyroid receptor-β (TRβ)-selective agonist GC-1 (sobetirome) from a novel nanochannel membrane device (NMD) for drug delivery. As it known to speed up metabolism, accomplish weight loss, improve cholesterol levels and possess anti-diabetic effects, GC-1 was steadily administered by our NMD, consisting of an implantable nanochannel membrane, as an alternative to conventional daily administration, which is subject to compliance issues in clinical settings. SUBJECTS/METHODS Diet-induced obese C57BL/J6 male mice were fed a very high-fat diet (VHFD) and received NMD implants subcutaneously. Ten mice per group received capsules containing GC-1 or phosphate-buffered saline (control). Weight, lean and fat mass, as well as cholesterol, triglycerides, insulin and glucose, were monitored for 24 days. After treatment, plasma levels of thyroid-stimulating hormone (TSH) and thyroxine were compared. mRNA levels of a panel of thermogenic markers were examined using real-time PCR in white adipose tissue (WAT) and brown adipose tissue (BAT). Adipose tissue, liver and local inflammatory response to the implant were examined histologically. Pancreatic islet number and β-cell area were assessed. RESULTS GC-1 released from the NMD reversed VHFD-induced obesity and normalized serum cholesterol and glycemia. Significant reductions in body weight and fat mass were observed within 10 days, whereas reductions in serum cholesterol and glucose levels were seen within 7 days. The significant decrease in TSH was consistent with TRβ selectivity for GC-1. Levels of transcript for Ucp1 and thermogenic genes PGC1a, Cidea, Dio2 and Cox5a showed significant upregulation in WAT in NMD-GC-1-treated mice, but decreased in BAT. Although mice treated by NMD-GC-1 showed a similar number of pancreatic islets, they exhibited significant increase in β-cell area. CONCLUSIONS Our data demonstrate that the NMD implant achieves steady administration of GC-1, offering an effective and tightly controlled molecular delivery system for treatment of obesity and metabolic disease, thereby addressing compliance.
Collapse
Affiliation(s)
- C S Filgueira
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA
| | - E Nicolov
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA
| | - R L Hood
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA
| | - A Ballerini
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA.,Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
| | - J Garcia-Huidobro
- Deparment of Human Genetics, Miller School of Medicine, University of Miami, Miami, FL, USA
| | - J Z Lin
- Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA
| | - D Fraga
- Department of Surgery, The Methodist Hospital, Houston, TX, USA
| | - P Webb
- Genomic Medicine Program, Houston Methodist Research Institute, Houston, TX, USA
| | - O M Sabek
- Department of Surgery, The Methodist Hospital, Houston, TX, USA.,Department of Surgery, Weill Cornell Medical College, New York, NY, USA
| | - A O Gaber
- Department of Surgery, The Methodist Hospital, Houston, TX, USA.,Department of Surgery, Weill Cornell Medical College, New York, NY, USA
| | - K J Phillips
- Department of Molecular & Cellular Biology, Baylor College of Medicine, Houston, TX, USA
| | - A Grattoni
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA
| |
Collapse
|
20
|
Ohba K, Leow MKS, Singh BK, Sinha RA, Lesmana R, Liao XH, Ghosh S, Refetoff S, Sng JCG, Yen PM. Desensitization and Incomplete Recovery of Hepatic Target Genes After Chronic Thyroid Hormone Treatment and Withdrawal in Male Adult Mice. Endocrinology 2016; 157:1660-72. [PMID: 26866609 PMCID: PMC4816733 DOI: 10.1210/en.2015-1848] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Clinical symptoms may vary and not necessarily reflect serum thyroid hormone (TH) levels during acute and chronic hyperthyroidism as well as recovery from hyperthyroidism. We thus examined changes in hepatic gene expression and serum TH/TSH levels in adult male mice treated either with a single T3 (20 μg per 100 g body weight) injection (acute T3) or daily injections for 14 days (chronic T3) followed by 10 days of withdrawal. Gene expression arrays from livers harvested at these time points showed that among positively-regulated target genes, 320 were stimulated acutely and 429 chronically by T3. Surprisingly, only 69 of 680 genes (10.1%) were induced during both periods, suggesting desensitization of the majority of acutely stimulated target genes. About 90% of positively regulated target genes returned to baseline expression levels after 10 days of withdrawal; however, 67 of 680 (9.9%) did not return to baseline despite normalization of serum TH/TSH levels. Similar findings also were observed for negatively regulated target genes. Chromatin immunoprecipitation analysis of representative positively regulated target genes suggested that acetylation of H3K9/K14 was associated with acute stimulation, whereas trimethylation of H3K4 was associated with chronic stimulation. In an in vivo model of chronic intrahepatic hyperthyroidism since birth, adult male monocarboxylate transporter-8 knockout mice also demonstrated desensitization of most acutely stimulated target genes that were examined. In summary, we have identified transcriptional desensitization and incomplete recovery of gene expression during chronic hyperthyroidism and recovery. Our findings may be a potential reason for discordance between clinical symptoms and serum TH levels observed in these conditions.
Collapse
Affiliation(s)
- Kenji Ohba
- Cardiovascular and Metabolic Disorders Program (K.O., B.K.S., R.A.S., R.L., S.G., P.M.Y.), Duke-NUS Medical School, Singapore, Singapore 169857; Department of Endocrinology (M.K.-S.L.), Tan Tock Seng Hospital, Singapore, Singapore 229899; Singapore Institute for Clinical Sciences (M.K.-S.L.), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore 117609; Department of Physiology (R.L.), Universitas Padjadjaran, Bandung, West Java 45363, Indonesia; Departments of Medicine (X.-H.L., S.R.) and Pediatrics and Committee on Genetics (S.R.), The University of Chicago, Chicago, Illinois 60637; and Department of Pharmacology (J.C.G.S.), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore 119228
| | - Melvin Khee-Shing Leow
- Cardiovascular and Metabolic Disorders Program (K.O., B.K.S., R.A.S., R.L., S.G., P.M.Y.), Duke-NUS Medical School, Singapore, Singapore 169857; Department of Endocrinology (M.K.-S.L.), Tan Tock Seng Hospital, Singapore, Singapore 229899; Singapore Institute for Clinical Sciences (M.K.-S.L.), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore 117609; Department of Physiology (R.L.), Universitas Padjadjaran, Bandung, West Java 45363, Indonesia; Departments of Medicine (X.-H.L., S.R.) and Pediatrics and Committee on Genetics (S.R.), The University of Chicago, Chicago, Illinois 60637; and Department of Pharmacology (J.C.G.S.), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore 119228
| | - Brijesh Kumar Singh
- Cardiovascular and Metabolic Disorders Program (K.O., B.K.S., R.A.S., R.L., S.G., P.M.Y.), Duke-NUS Medical School, Singapore, Singapore 169857; Department of Endocrinology (M.K.-S.L.), Tan Tock Seng Hospital, Singapore, Singapore 229899; Singapore Institute for Clinical Sciences (M.K.-S.L.), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore 117609; Department of Physiology (R.L.), Universitas Padjadjaran, Bandung, West Java 45363, Indonesia; Departments of Medicine (X.-H.L., S.R.) and Pediatrics and Committee on Genetics (S.R.), The University of Chicago, Chicago, Illinois 60637; and Department of Pharmacology (J.C.G.S.), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore 119228
| | - Rohit Anthony Sinha
- Cardiovascular and Metabolic Disorders Program (K.O., B.K.S., R.A.S., R.L., S.G., P.M.Y.), Duke-NUS Medical School, Singapore, Singapore 169857; Department of Endocrinology (M.K.-S.L.), Tan Tock Seng Hospital, Singapore, Singapore 229899; Singapore Institute for Clinical Sciences (M.K.-S.L.), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore 117609; Department of Physiology (R.L.), Universitas Padjadjaran, Bandung, West Java 45363, Indonesia; Departments of Medicine (X.-H.L., S.R.) and Pediatrics and Committee on Genetics (S.R.), The University of Chicago, Chicago, Illinois 60637; and Department of Pharmacology (J.C.G.S.), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore 119228
| | - Ronny Lesmana
- Cardiovascular and Metabolic Disorders Program (K.O., B.K.S., R.A.S., R.L., S.G., P.M.Y.), Duke-NUS Medical School, Singapore, Singapore 169857; Department of Endocrinology (M.K.-S.L.), Tan Tock Seng Hospital, Singapore, Singapore 229899; Singapore Institute for Clinical Sciences (M.K.-S.L.), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore 117609; Department of Physiology (R.L.), Universitas Padjadjaran, Bandung, West Java 45363, Indonesia; Departments of Medicine (X.-H.L., S.R.) and Pediatrics and Committee on Genetics (S.R.), The University of Chicago, Chicago, Illinois 60637; and Department of Pharmacology (J.C.G.S.), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore 119228
| | - Xiao-Hui Liao
- Cardiovascular and Metabolic Disorders Program (K.O., B.K.S., R.A.S., R.L., S.G., P.M.Y.), Duke-NUS Medical School, Singapore, Singapore 169857; Department of Endocrinology (M.K.-S.L.), Tan Tock Seng Hospital, Singapore, Singapore 229899; Singapore Institute for Clinical Sciences (M.K.-S.L.), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore 117609; Department of Physiology (R.L.), Universitas Padjadjaran, Bandung, West Java 45363, Indonesia; Departments of Medicine (X.-H.L., S.R.) and Pediatrics and Committee on Genetics (S.R.), The University of Chicago, Chicago, Illinois 60637; and Department of Pharmacology (J.C.G.S.), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore 119228
| | - Sujoy Ghosh
- Cardiovascular and Metabolic Disorders Program (K.O., B.K.S., R.A.S., R.L., S.G., P.M.Y.), Duke-NUS Medical School, Singapore, Singapore 169857; Department of Endocrinology (M.K.-S.L.), Tan Tock Seng Hospital, Singapore, Singapore 229899; Singapore Institute for Clinical Sciences (M.K.-S.L.), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore 117609; Department of Physiology (R.L.), Universitas Padjadjaran, Bandung, West Java 45363, Indonesia; Departments of Medicine (X.-H.L., S.R.) and Pediatrics and Committee on Genetics (S.R.), The University of Chicago, Chicago, Illinois 60637; and Department of Pharmacology (J.C.G.S.), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore 119228
| | - Samuel Refetoff
- Cardiovascular and Metabolic Disorders Program (K.O., B.K.S., R.A.S., R.L., S.G., P.M.Y.), Duke-NUS Medical School, Singapore, Singapore 169857; Department of Endocrinology (M.K.-S.L.), Tan Tock Seng Hospital, Singapore, Singapore 229899; Singapore Institute for Clinical Sciences (M.K.-S.L.), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore 117609; Department of Physiology (R.L.), Universitas Padjadjaran, Bandung, West Java 45363, Indonesia; Departments of Medicine (X.-H.L., S.R.) and Pediatrics and Committee on Genetics (S.R.), The University of Chicago, Chicago, Illinois 60637; and Department of Pharmacology (J.C.G.S.), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore 119228
| | - Judy Chia Ghee Sng
- Cardiovascular and Metabolic Disorders Program (K.O., B.K.S., R.A.S., R.L., S.G., P.M.Y.), Duke-NUS Medical School, Singapore, Singapore 169857; Department of Endocrinology (M.K.-S.L.), Tan Tock Seng Hospital, Singapore, Singapore 229899; Singapore Institute for Clinical Sciences (M.K.-S.L.), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore 117609; Department of Physiology (R.L.), Universitas Padjadjaran, Bandung, West Java 45363, Indonesia; Departments of Medicine (X.-H.L., S.R.) and Pediatrics and Committee on Genetics (S.R.), The University of Chicago, Chicago, Illinois 60637; and Department of Pharmacology (J.C.G.S.), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore 119228
| | - Paul Michael Yen
- Cardiovascular and Metabolic Disorders Program (K.O., B.K.S., R.A.S., R.L., S.G., P.M.Y.), Duke-NUS Medical School, Singapore, Singapore 169857; Department of Endocrinology (M.K.-S.L.), Tan Tock Seng Hospital, Singapore, Singapore 229899; Singapore Institute for Clinical Sciences (M.K.-S.L.), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore 117609; Department of Physiology (R.L.), Universitas Padjadjaran, Bandung, West Java 45363, Indonesia; Departments of Medicine (X.-H.L., S.R.) and Pediatrics and Committee on Genetics (S.R.), The University of Chicago, Chicago, Illinois 60637; and Department of Pharmacology (J.C.G.S.), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore 119228
| |
Collapse
|
21
|
McAninch EA, Miller BT, Ueta CB, Jo S, Kim BW. Thyroid Hormone at Near Physiologic Concentrations Acutely Increases Oxygen Consumption and Extracellular Acidification in LH86 Hepatoma Cells. Endocrinology 2015; 156:4325-35. [PMID: 26287403 DOI: 10.1210/en.2015-1221] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Thyroid hormone (T3) has been known to regulate the basal metabolic rate for more than a century, but mechanistic understanding is lacking both at the level of the intact organism and in terms of how T3 alters energy expenditure in individual tissues. The current studies investigate the question of which metabolically relevant genes respond acutely as T3 concentrations increase through the physiologic range in liver cells. Because this has been technically unfeasible historically, we developed a modified protocol for extracellular flux analysis using a 96-well Extracellular Flux Analyzer (Seahorse Bioscience). Using a modified extracellular flux protocol and LH86 human hepatoma cells, we established an experimental system where small but significant changes in O2 consumption could be reproducibly quantified as hypothyroid cells were exposed to near-physiologic final concentrations of T3 approximately 2 orders of magnitude lower than most studies (0.04 nM free T3), in only 6-7 hours. Taking advantage of the nondestructive nature of 96-well Extracellular Flux Analyzer measurements, the acute, direct, transcriptional changes that occur were measured in the exact same cells demonstrating increased O2 consumption. An unbiased, genome-wide microarray analysis identified potential candidate genes related to fatty acid oxidation, angiogenesis, nucleotide metabolism, immune signaling, mitochondrial respiration, and cell proliferation. The identified transcriptome is likely enriched in the genes most important for mediating the energetic effects of T3 in hepatoma cells.
Collapse
Affiliation(s)
- Elizabeth A McAninch
- Division of Endocrinology and Metabolism (E.A.M., S.J., B.W.K.), Rush University Medical Center, Chicago, Illinois 60612; University of South Florida Morsani College of Medicine (B.T.M.), Tampa, Florida 33612; and Institute of Biomedical Science (C.B.U.), University of São Paulo, São Paulo SP 05508-000, Brazil
| | - Bradford T Miller
- Division of Endocrinology and Metabolism (E.A.M., S.J., B.W.K.), Rush University Medical Center, Chicago, Illinois 60612; University of South Florida Morsani College of Medicine (B.T.M.), Tampa, Florida 33612; and Institute of Biomedical Science (C.B.U.), University of São Paulo, São Paulo SP 05508-000, Brazil
| | - Cintia B Ueta
- Division of Endocrinology and Metabolism (E.A.M., S.J., B.W.K.), Rush University Medical Center, Chicago, Illinois 60612; University of South Florida Morsani College of Medicine (B.T.M.), Tampa, Florida 33612; and Institute of Biomedical Science (C.B.U.), University of São Paulo, São Paulo SP 05508-000, Brazil
| | - Sungro Jo
- Division of Endocrinology and Metabolism (E.A.M., S.J., B.W.K.), Rush University Medical Center, Chicago, Illinois 60612; University of South Florida Morsani College of Medicine (B.T.M.), Tampa, Florida 33612; and Institute of Biomedical Science (C.B.U.), University of São Paulo, São Paulo SP 05508-000, Brazil
| | - Brian W Kim
- Division of Endocrinology and Metabolism (E.A.M., S.J., B.W.K.), Rush University Medical Center, Chicago, Illinois 60612; University of South Florida Morsani College of Medicine (B.T.M.), Tampa, Florida 33612; and Institute of Biomedical Science (C.B.U.), University of São Paulo, São Paulo SP 05508-000, Brazil
| |
Collapse
|
22
|
Cvoro A, Devito L, Milton FA, Noli L, Zhang A, Filippi C, Sakai K, Suh JH, H Sieglaff D, Dhawan A, Sakai T, Ilic D, Webb P. A thyroid hormone receptor/KLF9 axis in human hepatocytes and pluripotent stem cells. Stem Cells 2015; 33:416-28. [PMID: 25330987 PMCID: PMC6317531 DOI: 10.1002/stem.1875] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2014] [Revised: 08/21/2014] [Accepted: 09/13/2014] [Indexed: 12/15/2022]
Abstract
Biological processes require close cooperation of multiple transcription factors that integrate different signals. Thyroid hormone receptors (TRs) induce Krüppel-like factor 9 (KLF9) to regulate neurogenesis. Here, we show that triiodothyronine (T3) also works through TR to induce KLF9 in HepG2 liver cells, mouse liver, and mouse and human primary hepatocytes and sought to understand TR/KLF9 network function in the hepatocyte lineage and stem cells. Knockdown experiments reveal that KLF9 regulates hundreds of HepG2 target genes and modulates T3 response. Together, T3 and KLF9 target genes influence pathways implicated in stem cell self-renewal and differentiation, including Notch signaling, and we verify that T3 and KLF9 cooperate to regulate key Notch pathway genes and work independently to regulate others. T3 also induces KLF9 in human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSC) and this effect persists during differentiation to definitive endoderm and hiPSC-derived hepatocytes. Microarray analysis reveals that T3 regulates hundreds of hESC and hiPSC target genes that cluster into many of the same pathways implicated in TR and KLF9 regulation in HepG2 cells. KLF9 knockdown confirms that TR and KLF9 cooperate to regulate Notch pathway genes in hESC and hiPSC, albeit in a partly cell-specific manner. Broader analysis of T3 responsive hESC/hiPSC genes suggests that TRs regulate multiple early steps in ESC differentiation. We propose that TRs cooperate with KLF9 to regulate hepatocyte proliferation and differentiation and early stages of organogenesis and that TRs exert widespread and important influences on ESC biology.
Collapse
Affiliation(s)
- Aleksandra Cvoro
- Genomic Medicine, Houston Methodist Research Institute, Houston, Texas, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Martagón AJ, Lin JZ, Cimini SL, Webb P, Phillips KJ. The amelioration of hepatic steatosis by thyroid hormone receptor agonists is insufficient to restore insulin sensitivity in ob/ob mice. PLoS One 2015; 10:e0122987. [PMID: 25849936 PMCID: PMC4388544 DOI: 10.1371/journal.pone.0122987] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2014] [Accepted: 02/26/2015] [Indexed: 12/13/2022] Open
Abstract
Thyroid hormone receptor (TR) agonists have been proposed as therapeutic agents to treat non-alcoholic fatty liver disease (NAFLD) and insulin resistance. We investigated the ability of the TR agonists GC-1 and KB2115 to reduce hepatic steatosis in ob/ob mice. Both compounds markedly reduced hepatic triglyceride levels and ameliorated hepatic steatosis. However, the amelioration of fatty liver was not sufficient to improve insulin sensitivity in these mice and reductions in hepatic triglycerides did not correlate with improvements in insulin sensitivity or glycemic control. Instead, the effects of TR activation on glycemia varied widely and were found to depend upon the time of treatment as well as the compound and dosage used. Lower doses of GC-1 were found to further impair glycemic control, while a higher dose of the same compound resulted in substantially improved glucose tolerance and insulin sensitivity, despite all doses being equally effective at reducing hepatic triglyceride levels. Improvements in glycemic control and insulin sensitivity were observed only in treatments that also increased body temperature, suggesting that the induction of thermogenesis may play a role in mediating these beneficial effects. These data illustrate that the relationship between TR activation and insulin sensitivity is complex and suggests that although TR agonists may have value in treating NAFLD, their effect on insulin sensitivity must also be considered.
Collapse
Affiliation(s)
- Alexandro J. Martagón
- Diabetes and Metabolic Disease Program, Houston Methodist Research Institute, Houston, Texas, United States of America
- Escuela de Biotecnología y Alimentos, Instituto Tecnológico y de Estudios Superiores de Monterrey, Monterrey, NL, Mexico
| | - Jean Z. Lin
- Diabetes and Metabolic Disease Program, Houston Methodist Research Institute, Houston, Texas, United States of America
- Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, Texas, United States of America
| | - Stephanie L. Cimini
- Diabetes and Metabolic Disease Program, Houston Methodist Research Institute, Houston, Texas, United States of America
| | - Paul Webb
- Diabetes and Metabolic Disease Program, Houston Methodist Research Institute, Houston, Texas, United States of America
| | - Kevin J. Phillips
- Diabetes and Metabolic Disease Program, Houston Methodist Research Institute, Houston, Texas, United States of America
- * E-mail:
| |
Collapse
|
24
|
Zhang A, Sieglaff DH, York JP, Suh JH, Ayers SD, Winnier GE, Kharitonenkov A, Pin C, Zhang P, Webb P, Xia X. Thyroid hormone receptor regulates most genes independently of fibroblast growth factor 21 in liver. J Endocrinol 2015; 224:289-301. [PMID: 25501997 DOI: 10.1530/joe-14-0440] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Thyroid hormone (TH) acts through specific receptors (TRs), which are conditional transcription factors, to induce fibroblast growth factor 21 (FGF21), a peptide hormone that is usually induced by fasting and that influences lipid and carbohydrate metabolism via local hepatic and systemic endocrine effects. While TH and FGF21 display overlapping actions when administered, including reductions in serum lipids, according to the current models these hormones act independently in vivo. In this study, we examined mechanisms of regulation of FGF21 expression by TH and tested the possibility that FGF21 is required for induction of hepatic TH-responsive genes. We confirm that active TH (triiodothyronine (T3)) and the TRβ-selective thyromimetic GC1 increase FGF21 transcript and peptide levels in mouse liver and that this effect requires TRβ. T3 also induces FGF21 in cultured hepatocytes and this effect involves direct actions of TRβ1, which binds a TRE within intron 2 of FGF21. Gene expression profiles of WT and Fgf21-knockout mice are very similar, indicating that FGF21 is dispensable for the majority of hepatic T3 gene responses. A small subset of genes displays diminished T3 response in the absence of FGF21. However, most of these are not obviously directly involved in T3-dependent hepatic metabolic processes. Consistent with these results, T3-dependent effects on serum cholesterol are maintained in the Fgf21(-/-) background and we observe no effect of the Fgf21-knockout background on serum triglycerides and glucose. Our findings indicate that T3 regulates the genes involved in classical hepatic metabolic responses independently of FGF21.
Collapse
Affiliation(s)
- Aijun Zhang
- Houston Methodist Research InstituteGenomic Medicine Program, 6670 Bertner Ave, Houston, Texas 77030, USACollege of Arts and SciencesChemistry Department, Indiana University Bloomington, Bloomington, Indiana, USADepartments of PaediatricsOncology, and Physiology and Pharmacology, University of Western Ontario, London, Ontario, CanadaChildren's Health Research InstituteLondon, Ontario, CanadaDepartment of Molecular Physiology and BiophysicsBaylor College of Medicine, Houston, Texas, USAThe Third Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, China
| | - Douglas H Sieglaff
- Houston Methodist Research InstituteGenomic Medicine Program, 6670 Bertner Ave, Houston, Texas 77030, USACollege of Arts and SciencesChemistry Department, Indiana University Bloomington, Bloomington, Indiana, USADepartments of PaediatricsOncology, and Physiology and Pharmacology, University of Western Ontario, London, Ontario, CanadaChildren's Health Research InstituteLondon, Ontario, CanadaDepartment of Molecular Physiology and BiophysicsBaylor College of Medicine, Houston, Texas, USAThe Third Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, China
| | - Jean Philippe York
- Houston Methodist Research InstituteGenomic Medicine Program, 6670 Bertner Ave, Houston, Texas 77030, USACollege of Arts and SciencesChemistry Department, Indiana University Bloomington, Bloomington, Indiana, USADepartments of PaediatricsOncology, and Physiology and Pharmacology, University of Western Ontario, London, Ontario, CanadaChildren's Health Research InstituteLondon, Ontario, CanadaDepartment of Molecular Physiology and BiophysicsBaylor College of Medicine, Houston, Texas, USAThe Third Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, China
| | - Ji Ho Suh
- Houston Methodist Research InstituteGenomic Medicine Program, 6670 Bertner Ave, Houston, Texas 77030, USACollege of Arts and SciencesChemistry Department, Indiana University Bloomington, Bloomington, Indiana, USADepartments of PaediatricsOncology, and Physiology and Pharmacology, University of Western Ontario, London, Ontario, CanadaChildren's Health Research InstituteLondon, Ontario, CanadaDepartment of Molecular Physiology and BiophysicsBaylor College of Medicine, Houston, Texas, USAThe Third Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, China
| | - Stephen D Ayers
- Houston Methodist Research InstituteGenomic Medicine Program, 6670 Bertner Ave, Houston, Texas 77030, USACollege of Arts and SciencesChemistry Department, Indiana University Bloomington, Bloomington, Indiana, USADepartments of PaediatricsOncology, and Physiology and Pharmacology, University of Western Ontario, London, Ontario, CanadaChildren's Health Research InstituteLondon, Ontario, CanadaDepartment of Molecular Physiology and BiophysicsBaylor College of Medicine, Houston, Texas, USAThe Third Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, China
| | - Glenn E Winnier
- Houston Methodist Research InstituteGenomic Medicine Program, 6670 Bertner Ave, Houston, Texas 77030, USACollege of Arts and SciencesChemistry Department, Indiana University Bloomington, Bloomington, Indiana, USADepartments of PaediatricsOncology, and Physiology and Pharmacology, University of Western Ontario, London, Ontario, CanadaChildren's Health Research InstituteLondon, Ontario, CanadaDepartment of Molecular Physiology and BiophysicsBaylor College of Medicine, Houston, Texas, USAThe Third Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, China
| | - Alexei Kharitonenkov
- Houston Methodist Research InstituteGenomic Medicine Program, 6670 Bertner Ave, Houston, Texas 77030, USACollege of Arts and SciencesChemistry Department, Indiana University Bloomington, Bloomington, Indiana, USADepartments of PaediatricsOncology, and Physiology and Pharmacology, University of Western Ontario, London, Ontario, CanadaChildren's Health Research InstituteLondon, Ontario, CanadaDepartment of Molecular Physiology and BiophysicsBaylor College of Medicine, Houston, Texas, USAThe Third Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, China
| | - Christopher Pin
- Houston Methodist Research InstituteGenomic Medicine Program, 6670 Bertner Ave, Houston, Texas 77030, USACollege of Arts and SciencesChemistry Department, Indiana University Bloomington, Bloomington, Indiana, USADepartments of PaediatricsOncology, and Physiology and Pharmacology, University of Western Ontario, London, Ontario, CanadaChildren's Health Research InstituteLondon, Ontario, CanadaDepartment of Molecular Physiology and BiophysicsBaylor College of Medicine, Houston, Texas, USAThe Third Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, China Houston Methodist Research InstituteGenomic Medicine Program, 6670 Bertner Ave, Houston, Texas 77030, USACollege of Arts and SciencesChemistry Department, Indiana University Bloomington, Bloomington, Indiana, USADepartments of PaediatricsOncology, and Physiology and Pharmacology, University of Western Ontario, London, Ontario, CanadaChildren's Health Research InstituteLondon, Ontario, CanadaDepartment of Molecular Physiology and BiophysicsBaylor College of Medicine, Houston, Texas, USAThe Third Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, China
| | - Pumin Zhang
- Houston Methodist Research InstituteGenomic Medicine Program, 6670 Bertner Ave, Houston, Texas 77030, USACollege of Arts and SciencesChemistry Department, Indiana University Bloomington, Bloomington, Indiana, USADepartments of PaediatricsOncology, and Physiology and Pharmacology, University of Western Ontario, London, Ontario, CanadaChildren's Health Research InstituteLondon, Ontario, CanadaDepartment of Molecular Physiology and BiophysicsBaylor College of Medicine, Houston, Texas, USAThe Third Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, China
| | - Paul Webb
- Houston Methodist Research InstituteGenomic Medicine Program, 6670 Bertner Ave, Houston, Texas 77030, USACollege of Arts and SciencesChemistry Department, Indiana University Bloomington, Bloomington, Indiana, USADepartments of PaediatricsOncology, and Physiology and Pharmacology, University of Western Ontario, London, Ontario, CanadaChildren's Health Research InstituteLondon, Ontario, CanadaDepartment of Molecular Physiology and BiophysicsBaylor College of Medicine, Houston, Texas, USAThe Third Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, China
| | - Xuefeng Xia
- Houston Methodist Research InstituteGenomic Medicine Program, 6670 Bertner Ave, Houston, Texas 77030, USACollege of Arts and SciencesChemistry Department, Indiana University Bloomington, Bloomington, Indiana, USADepartments of PaediatricsOncology, and Physiology and Pharmacology, University of Western Ontario, London, Ontario, CanadaChildren's Health Research InstituteLondon, Ontario, CanadaDepartment of Molecular Physiology and BiophysicsBaylor College of Medicine, Houston, Texas, USAThe Third Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, China Houston Methodist Research InstituteGenomic Medicine Program, 6670 Bertner Ave, Houston, Texas 77030, USACollege of Arts and SciencesChemistry Department, Indiana University Bloomington, Bloomington, Indiana, USADepartments of PaediatricsOncology, and Physiology and Pharmacology, University of Western Ontario, London, Ontario, CanadaChildren's Health Research InstituteLondon, Ontario, CanadaDepartment of Molecular Physiology and BiophysicsBaylor College of Medicine, Houston, Texas, USAThe Third Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, China
| |
Collapse
|
25
|
Chatonnet F, Livera G, Fumel B, FouchÉCourt S, Flamant F. Direct and indirect consequences on gene expression of a thyroid hormone receptor alpha 1 mutation restricted to Sertoli cells. Mol Reprod Dev 2014; 81:1159-66. [PMID: 25487743 DOI: 10.1002/mrd.22437] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2014] [Accepted: 10/22/2014] [Indexed: 01/29/2023]
Abstract
Thyroid hormone is required for the timely transition of Sertoli cells from proliferative to differentiating and maturing. This transition takes place during a critical developmental period in mammals, which in mice is the first post-natal week. In order to identify the underlying molecular mechanisms of this differentiation process, we used Cre/loxP technology to selectively block the function of the thyroid hormone receptor TRα1 in Sertoli cells. We then used RNA-seq to analyze the changes in gene expression induced in the post-natal testis. This differential analysis provides genetic clues to the initial testicular defects resulting from disrupted thyroid hormone signaling, and suggests that Sertoli cells influence germ cells soon after their birth.
Collapse
Affiliation(s)
- Fabrice Chatonnet
- Institut de Génomique Fonctionnelle de Lyon, Université de Lyon, Université Lyon 1, INRA, CNRS, Cedex, France
| | | | | | | | | |
Collapse
|
26
|
Lammel Lindemann JA, Angajala A, Engler DA, Webb P, Ayers SD. Thyroid hormone induction of human cholesterol 7 alpha-hydroxylase (Cyp7a1) in vitro. Mol Cell Endocrinol 2014; 388:32-40. [PMID: 24582860 PMCID: PMC4180720 DOI: 10.1016/j.mce.2014.02.003] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/18/2013] [Revised: 01/21/2014] [Accepted: 02/07/2014] [Indexed: 02/01/2023]
Abstract
Thyroid hormone (TH) modulates serum cholesterol by acting on TH receptor β1 (TRβ1) in liver to regulate metabolic gene sets. In rodents, one important TH regulated step involves induction of Cyp7a1, an enzyme in the cytochrome P450 family, which enhances cholesterol to bile acid conversion and plays a crucial role in regulation of serum cholesterol levels. Current models suggest, however, that Cyp7a1 has lost the capacity to respond to THs in humans. We were prompted to re-examine TH effects on cholesterol metabolic genes in human liver cells by a recent study of a synthetic TH mimetic which showed that serum cholesterol reductions were accompanied by increases in a marker for bile acid synthesis in humans. Here, we show that TH effects upon cholesterol metabolic genes are almost identical in mouse liver, mouse and human liver primary cells and human hepatocyte cell lines. Moreover, Cyp7a1 is a direct TR target gene that responds to physiologic TR levels through a set of distinct response elements in its promoter. These findings suggest that THs regulate cholesterol to bile acid conversion in similar ways in humans and rodent experimental models and that manipulation of hormone signaling pathways could provide a strategy to enhance Cyp7a1 activity in human patients.
Collapse
Affiliation(s)
- Jan A Lammel Lindemann
- Houston Methodist Research Institute, Houston, Texas, United States; Escuela de Biotecnología y Alimentos, Instituto Tecnológico y de Estudios Superiores de Monterrey, Mexico
| | - Anusha Angajala
- Houston Methodist Research Institute, Houston, Texas, United States
| | - David A Engler
- Houston Methodist Research Institute, Houston, Texas, United States
| | - Paul Webb
- Houston Methodist Research Institute, Houston, Texas, United States; Escuela de Biotecnología y Alimentos, Instituto Tecnológico y de Estudios Superiores de Monterrey, Mexico.
| | - Stephen D Ayers
- Houston Methodist Research Institute, Houston, Texas, United States.
| |
Collapse
|
27
|
Astapova I, Ramadoss P, Costa-e-Sousa RH, Ye F, Holtz KA, Li Y, Niepel MW, Cohen DE, Hollenberg AN. Hepatic nuclear corepressor 1 regulates cholesterol absorption through a TRβ1-governed pathway. J Clin Invest 2014; 124:1976-86. [PMID: 24713658 DOI: 10.1172/jci73419] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2013] [Accepted: 02/13/2014] [Indexed: 12/22/2022] Open
Abstract
Transcriptional coregulators are important components of nuclear receptor (NR) signaling machinery and provide additional mechanisms for modulation of NR activity. Expression of a mutated nuclear corepressor 1 (NCoR1) that lacks 2 NR interacting domains (NCoRΔID) in the liver leads to elevated expression of genes regulated by thyroid hormone receptor (TR) and liver X receptor (LXR), both of which control hepatic cholesterol metabolism. Here, we demonstrate that expression of NCoRΔID in mouse liver improves dietary cholesterol tolerance in an LXRα-independent manner. NCoRΔID-associated cholesterol tolerance was primarily due to diminished intestinal cholesterol absorption as the result of changes in the composition and hydrophobicity of the bile salt pool. Alterations of the bile salt pool were mediated by increased expression of genes encoding the bile acid metabolism enzymes CYP27A1 and CYP3A11 as well as canalicular bile salt pump ABCB11. We have determined that these genes are regulated by thyroid hormone and that TRβ1 is recruited to their regulatory regions. Together, these data indicate that interactions between NCoR1 and TR control a specific pathway involved in regulation of cholesterol metabolism and clearance.
Collapse
|
28
|
Ayers S, Switnicki MP, Angajala A, Lammel J, Arumanayagam AS, Webb P. Genome-wide binding patterns of thyroid hormone receptor beta. PLoS One 2014; 9:e81186. [PMID: 24558356 PMCID: PMC3928038 DOI: 10.1371/journal.pone.0081186] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2013] [Accepted: 10/16/2013] [Indexed: 12/15/2022] Open
Abstract
Thyroid hormone (TH) receptors (TRs) play central roles in metabolism and are major targets for pharmaceutical intervention. Presently, however, there is limited information about genome wide localizations of TR binding sites. Thus, complexities of TR genomic distribution and links between TRβ binding events and gene regulation are not fully appreciated. Here, we employ a BioChIP approach to capture TR genome-wide binding events in a liver cell line (HepG2). Like other NRs, TRβ appears widely distributed throughout the genome. Nevertheless, there is striking enrichment of TRβ binding sites immediately 5′ and 3′ of transcribed genes and TRβ can be detected near 50% of T3 induced genes. In contrast, no significant enrichment of TRβ is seen at negatively regulated genes or genes that respond to unliganded TRs in this system. Canonical TRE half-sites are present in more than 90% of TRβ peaks and classical TREs are also greatly enriched, but individual TRE organization appears highly variable with diverse half-site orientation and spacing. There is also significant enrichment of binding sites for TR associated transcription factors, including AP-1 and CTCF, near TR peaks. We conclude that T3-dependent gene induction commonly involves proximal TRβ binding events but that far-distant binding events are needed for T3 induction of some genes and that distinct, indirect, mechanisms are often at play in negative regulation and unliganded TR actions. Better understanding of genomic context of TR binding sites will help us determine why TR regulates genes in different ways and determine possibilities for selective modulation of TR action.
Collapse
Affiliation(s)
- Stephen Ayers
- The Methodist Hospital Research Institute, Genomic Medicine Program, Houston, Texas, United States of America
| | - Michal Piotr Switnicki
- The Methodist Hospital Research Institute, Genomic Medicine Program, Houston, Texas, United States of America
| | - Anusha Angajala
- The Methodist Hospital Research Institute, Genomic Medicine Program, Houston, Texas, United States of America
| | - Jan Lammel
- The Methodist Hospital Research Institute, Genomic Medicine Program, Houston, Texas, United States of America
- Tecnologico de Monterrey School of Medicine, Monterrey, NL, Mexico
| | | | - Paul Webb
- The Methodist Hospital Research Institute, Genomic Medicine Program, Houston, Texas, United States of America
- * E-mail:
| |
Collapse
|
29
|
Bianco AC, Anderson G, Forrest D, Galton VA, Gereben B, Kim BW, Kopp PA, Liao XH, Obregon MJ, Peeters RP, Refetoff S, Sharlin DS, Simonides WS, Weiss RE, Williams GR. American Thyroid Association Guide to investigating thyroid hormone economy and action in rodent and cell models. Thyroid 2014; 24:88-168. [PMID: 24001133 PMCID: PMC3887458 DOI: 10.1089/thy.2013.0109] [Citation(s) in RCA: 143] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND An in-depth understanding of the fundamental principles that regulate thyroid hormone homeostasis is critical for the development of new diagnostic and treatment approaches for patients with thyroid disease. SUMMARY Important clinical practices in use today for the treatment of patients with hypothyroidism, hyperthyroidism, or thyroid cancer are the result of laboratory discoveries made by scientists investigating the most basic aspects of thyroid structure and molecular biology. In this document, a panel of experts commissioned by the American Thyroid Association makes a series of recommendations related to the study of thyroid hormone economy and action. These recommendations are intended to promote standardization of study design, which should in turn increase the comparability and reproducibility of experimental findings. CONCLUSIONS It is expected that adherence to these recommendations by investigators in the field will facilitate progress towards a better understanding of the thyroid gland and thyroid hormone dependent processes.
Collapse
Affiliation(s)
- Antonio C. Bianco
- Division of Endocrinology, Diabetes and Metabolism, University of Miami Miller School of Medicine, Miami, Florida
| | - Grant Anderson
- Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota Duluth, Duluth, Minnesota
| | - Douglas Forrest
- Laboratory of Endocrinology and Receptor Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
| | - Valerie Anne Galton
- Department of Physiology and Neurobiology, Dartmouth Medical School, Lebanon, New Hampshire
| | - Balázs Gereben
- Department of Endocrine Neurobiology, Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest, Hungary
| | - Brian W. Kim
- Division of Endocrinology, Diabetes and Metabolism, University of Miami Miller School of Medicine, Miami, Florida
| | - Peter A. Kopp
- Division of Endocrinology, Metabolism, and Molecular Medicine, and Center for Genetic Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Xiao Hui Liao
- Section of Adult and Pediatric Endocrinology, Diabetes, and Metabolism, The University of Chicago, Chicago, Illinois
| | - Maria Jesus Obregon
- Institute of Biomedical Investigation (IIB), Spanish National Research Council (CSIC) and Autonomous University of Madrid, Madrid, Spain
| | - Robin P. Peeters
- Division of Endocrinology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Samuel Refetoff
- Section of Adult and Pediatric Endocrinology, Diabetes, and Metabolism, The University of Chicago, Chicago, Illinois
| | - David S. Sharlin
- Department of Biological Sciences, Minnesota State University, Mankato, Minnesota
| | - Warner S. Simonides
- Laboratory for Physiology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands
| | - Roy E. Weiss
- Section of Adult and Pediatric Endocrinology, Diabetes, and Metabolism, The University of Chicago, Chicago, Illinois
| | - Graham R. Williams
- Department of Medicine, Imperial College London, Hammersmith Campus, London, United Kingdom
| |
Collapse
|
30
|
Sadasivuni MK, Reddy BM, Singh J, Anup MO, Sunil V, Lakshmi MN, Yogeshwari S, Chacko SK, Pooja TL, Dandu A, Harish C, Gopala AS, Pratibha S, Naveenkumar BS, Pallavi PM, Verma MK, Moolemath Y, Somesh BP, Venkataranganna MV, Jagannath MR. CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models. Diabetol Metab Syndr 2014; 6:83. [PMID: 25143786 PMCID: PMC4138375 DOI: 10.1186/1758-5996-6-83] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/22/2014] [Accepted: 08/06/2014] [Indexed: 01/23/2023] Open
Abstract
BACKGROUND In addition to their role in growth, cellular differentiation and homeostasis Retinoid X Receptors (RXR) regulate multiple physiological and metabolic pathways in various organs that have beneficial glucose and lipid (cholesterol) lowering, insulin sensitizing and anti-obesity effects. Rexinoids, compounds that specifically binds and activate RXR, are therefore considered as potential therapeutics for treating metabolic syndrome. Apparently many of the rexinoids developed in the past increased triglycerides, caused hepatomegaly and also suppressed the thyroid hormone axis. The aim of this study is to evaluate CNX-013-B2, a potent and highly selective rexinoid, for its potential to treat multiple risk factors of the metabolic syndrome. METHODS CNX-013-B2 was selected in a screening system designed to identify compounds that selectively activated only a chosen sub-set of heterodimer partners of RXR of importance to treat insulin resistance. Male C57BL/6j mice (n = 10) on high fat diet (HFD) and 16 week old ob/ob mice (n = 8) were treated orally with CNX-013-B2 (10 mg/kg twice daily) or vehicle for 10 weeks and 4 weeks respectively. Measurement of plasma glucose, triglyceride, cholesterol including LDL-C, glycerol, free fatty acids, feed intake, body weight, oral glucose tolerance and non-shivering thermogenesis were performed at selected time points. After study termination such measurements as organ weight, triglyceride content, mRNA levels, protein phosphorylation along with histological analysis were performed. RESULTS CNX-013-B2 selectively activates PPARs- α, β/δ and γ and modulates activity of LXR, THR and FXR. In ob/ob mice a significant reduction of 25% in fed glucose (p < 0.001 ), a 14% (p < 0.05) reduction in serum total cholesterol and 18% decrease (p < 0.01) in LDL-C and in DIO mice a reduction of 12% (p < 0.01 ) in fasting glucose, 20% in fed triglyceride (p < 0.01) and total cholesterol (p < 0.001) levels, coupled with enhanced insulin sensitivity, cold induced thermogenesis and 7% reduction in body weight were observed. CONCLUSION CNX-013-B2 is an orally bio available selective rexinoid that can be used as a novel therapeutic agent for management of multiple risk factors of the metabolic syndrome without the risk of side effects reported to be associated with rexinoids.
Collapse
|
31
|
Ramadoss P, Abraham BJ, Tsai L, Zhou Y, Costa-e-Sousa RH, Ye F, Bilban M, Zhao K, Hollenberg AN. Novel mechanism of positive versus negative regulation by thyroid hormone receptor β1 (TRβ1) identified by genome-wide profiling of binding sites in mouse liver. J Biol Chem 2013; 289:1313-28. [PMID: 24288132 DOI: 10.1074/jbc.m113.521450] [Citation(s) in RCA: 77] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
Triiodothyronine (T3) regulates key metabolic processes in the liver through the thyroid hormone receptor, TRβ1. However, the number of known target genes directly regulated by TRβ1 is limited, and the mechanisms by which positive and especially negative transcriptional regulation occur are not well understood. To characterize the TRβ1 cistrome in vivo, we expressed a biotinylated TRβ1 in hypo- and hyperthyroid mouse livers, used ChIP-seq to identify genomic TRβ1 targets, and correlated these data with gene expression changes. As with other nuclear receptors, the majority of TRβ1 binding sites were not in proximal promoters but in the gene body of known genes. Remarkably, T3 can dictate changes in TRβ1 binding, with strong correlation to T3-induced gene expression changes, suggesting that differential TRβ1 binding regulates transcriptional outcome. Additionally, DR-4 and DR-0 motifs were significantly enriched at binding sites where T3 induced an increase or decrease in TRβ1 binding, respectively, leading to either positive or negative regulation by T3. Taken together, the results of this study provide new insights into the mechanisms of transcriptional regulation by TRβ1 in vivo.
Collapse
Affiliation(s)
- Preeti Ramadoss
- From the Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Katchy A, Pinto C, Jonsson P, Nguyen-Vu T, Pandelova M, Riu A, Schramm KW, Samarov D, Gustafsson JÅ, Bondesson M, Williams C. Coexposure to phytoestrogens and bisphenol a mimics estrogenic effects in an additive manner. Toxicol Sci 2013; 138:21-35. [PMID: 24284790 DOI: 10.1093/toxsci/kft271] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Endocrine-disrupting chemicals (EDC) are abundant in our environment. A number of EDCs, including bisphenol A (BPA) can bind to the estrogen receptors (ER), ERα and ERβ, and may contribute to estrogen-linked diseases such as breast cancer. Early exposure is of particular concern; many EDCs cross the placenta and infants have measurable levels of, eg, BPA. In addition, infants are frequently fed soy-based formula (SF) that contains phytoestrogens. Effects of combined exposure to xeno- and phytoestrogens are poorly studied. Here, we extensively compared to what extent BPA, genistein, and an extract of infant SF mimic estrogen-induced gene transcription and cell proliferation. We investigated ligand-specific effects on ER activation in HeLa-ERα and ERβ reporter cells; on proliferation, genome-wide gene regulation and non-ER-mediated effects in MCF7 breast cancer cells; and how coexposure influenced these effects. The biological relevance was explored using enrichment analyses of differentially regulated genes and clustering with clinical breast cancer profiles. We demonstrate that coexposure to BPA and genistein, or SF, results in increased functional and transcriptional estrogenic effects. Using statistical modeling, we determine that BPA and phytoestrogens act in an additive manner. The proliferative and transcriptional effects of the tested compounds mimic those of 17β-estradiol, and are abolished by cotreatment with an ER antagonist. Gene expression profiles induced by each compound clustered with poor prognosis breast cancer, indicating that exposure may adversely affect breast cancer prognosis. This study accentuates that coexposure to BPA and soy-based phytoestrogens results in additive estrogenic effects, and may contribute to estrogen-linked diseases, including breast cancer.
Collapse
Affiliation(s)
- Anne Katchy
- * Center for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, Texas 77204-5056
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Abstract
Thyroid hormones (THs) are important in the development and maintenance of lipid and energy homeostasis. THs act through two closely related TH receptors (TRs α and β), which are conditional transcription factors. Recently, TH analogues or thyromimetics with varying degrees of TR subtype and liver uptake selectivity have been developed. These compounds exert beneficial effects of TH excess states without many undesirable TR-dependent side effects. Several selective TR modulators (STRMs) showed exceptionally promising results in lowering serum cholesterol in preclinical animal models and human clinical studies. Moreover, some first generation STRMs elicit other potentially beneficial effects on obesity, glucose metabolism, and nonalcoholic fatty liver disease (NAFLD). While it was initially thought that STRMs would be an effective long-term therapy to combat elevated cholesterol, possibly in conjunction with another cholesterol-lowering therapy, the statins, three major first generation STRMs failed to progress beyond early phase III human trials. The aim of this review is to discuss how STRMs work, their actions in preclinical animal models and human clinical trials, why they did not progress beyond clinical trials as cholesterol-lowering therapeutics, whether selective TR modulation continues to hold promise for dyslipidemias, and whether members of this drug class could be applied to the treatment of other aspects of metabolic syndrome and human genetic disease.
Collapse
Affiliation(s)
- Sunitha Meruvu
- Center for Genomic Medicine, Houston Methodist Research Institute , Houston, Texas
| | | | | | | |
Collapse
|
34
|
Suh JH, Sieglaff DH, Zhang A, Xia X, Cvoro A, Winnier GE, Webb P. SIRT1 is a direct coactivator of thyroid hormone receptor β1 with gene-specific actions. PLoS One 2013; 8:e70097. [PMID: 23922917 PMCID: PMC3724829 DOI: 10.1371/journal.pone.0070097] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2013] [Accepted: 06/15/2013] [Indexed: 02/07/2023] Open
Abstract
Sirtuin 1 (SIRT1) NAD+-dependent deacetylase regulates energy metabolism by modulating expression of genes involved in gluconeogenesis and other liver fasting responses. While many effects of SIRT1 on gene expression are mediated by deacetylation and activation of peroxisome proliferator activated receptor coactivator α (PGC-1α), SIRT1 also binds directly to DNA bound transcription factors, including nuclear receptors (NRs), to modulate their activity. Since thyroid hormone receptor β1 (TRβ1) regulates several SIRT1 target genes in liver and interacts with PGC-1α, we hypothesized that SIRT1 may influence TRβ1. Here, we confirm that SIRT1 cooperates with PGC-1α to enhance response to triiodothyronine, T3. We also find, however, that SIRT1 stimulates TRβ1 activity in a manner that is independent of PGC-1α but requires SIRT1 deacetylase activity. SIRT1 interacts with TRβ1 in vitro, promotes TRβ1 deacetylation in the presence of T3 and enhances ubiquitin-dependent TRβ1 turnover; a common response of NRs to activating ligands. More surprisingly, SIRT1 knockdown only strongly inhibits T3 response of a subset of TRβ1 target genes, including glucose 6 phosphatase (G-6-Pc), and this is associated with blockade of TRβ1 binding to the G-6-Pc promoter. Drugs that target the SIRT1 pathway, resveratrol and nicotinamide, modulate T3 response at dual TRβ1/SIRT1 target genes. We propose that SIRT1 is a gene-specific TRβ1 co-regulator and TRβ1/SIRT1 interactions could play important roles in regulation of liver metabolic response. Our results open possibilities for modulation of subsets of TR target genes with drugs that influence the SIRT1 pathway.
Collapse
Affiliation(s)
- Ji Ho Suh
- Genomic Medicine Program, Methodist Hospital Research Institute, Houston, Texas, United States of America
| | - Douglas H. Sieglaff
- Genomic Medicine Program, Methodist Hospital Research Institute, Houston, Texas, United States of America
| | - Aijun Zhang
- Genomic Medicine Program, Methodist Hospital Research Institute, Houston, Texas, United States of America
| | - Xuefeng Xia
- Genomic Medicine Program, Methodist Hospital Research Institute, Houston, Texas, United States of America
| | - Aleksandra Cvoro
- Genomic Medicine Program, Methodist Hospital Research Institute, Houston, Texas, United States of America
| | - Glenn E. Winnier
- Genomic Medicine Program, Methodist Hospital Research Institute, Houston, Texas, United States of America
| | - Paul Webb
- Genomic Medicine Program, Methodist Hospital Research Institute, Houston, Texas, United States of America
- * E-mail:
| |
Collapse
|
35
|
Bernardes A, Souza PCT, Muniz JRC, Ricci CG, Ayers SD, Parekh NM, Godoy AS, Trivella DBB, Reinach P, Webb P, Skaf MS, Polikarpov I. Molecular mechanism of peroxisome proliferator-activated receptor α activation by WY14643: a new mode of ligand recognition and receptor stabilization. J Mol Biol 2013; 425:2878-93. [PMID: 23707408 DOI: 10.1016/j.jmb.2013.05.010] [Citation(s) in RCA: 74] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2012] [Revised: 04/30/2013] [Accepted: 05/15/2013] [Indexed: 01/01/2023]
Abstract
Peroxisome proliferator-activated receptors (PPARs) are members of a superfamily of nuclear transcription factors. They are involved in mediating numerous physiological effects in humans, including glucose and lipid metabolism. PPARα ligands effectively treat dyslipidemia and have significant antiinflammatory and anti-atherosclerotic activities. These effects and their ligand-dependent activity make nuclear receptors obvious targets for drug design. Here, we present the structure of the human PPARα in complex with WY14643, a member of fibrate class of drug, and a widely used PPAR activator. The crystal structure of this complex suggests that WY14643 induces activation of PPARα in an unusual bipartite mechanism involving conventional direct helix 12 stabilization and an alternative mode that involves a second ligand in the pocket. We present structural observations, molecular dynamics and activity assays that support the importance of the second site in WY14643 action. The unique binding mode of WY14643 reveals a new pattern of nuclear receptor ligand recognition and suggests a novel basis for ligand design, offering clues for improving the binding affinity and selectivity of ligand. We show that binding of WY14643 to PPARα was associated with antiinflammatory disease in a human corneal cell model, suggesting possible applications for PPARα ligands.
Collapse
Affiliation(s)
- Amanda Bernardes
- Institute of Physics of São Carlos, University of São Paulo, Avenida Trabalhador Sãocarlense 400, São Carlos, SP 13560-970, Brazil
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Gil-Ibañez P, Morte B, Bernal J. Role of thyroid hormone receptor subtypes α and β on gene expression in the cerebral cortex and striatum of postnatal mice. Endocrinology 2013; 154:1940-7. [PMID: 23493375 DOI: 10.1210/en.2012-2189] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
The effects of thyroid hormones (THs) on brain development and function are largely mediated by the control of gene expression. This is achieved by the binding of the genomically active T3 to transcriptionally active nuclear TH receptors (TRs). T3 and the TRs can either induce or repress transcription. In hypothyroidism, the reduction of T3 lowers the expression of a set of genes, the positively regulated genes, and increases the expression of negatively regulated genes. Two mechanisms may account for the effect of hypothyroidism on genes regulated directly by T3: first, the loss of T3 signaling and TR transactivation, and second, an intrinsic activity of the unliganded TRs directly responsible for repression of positive genes and enhancement of negative genes. To analyze the contribution of the TR subtypes α and β, we have measured by RT-PCR the expression of a set of positive and negative genes in the cerebral cortex and the striatum of TR-knockout male and female mice. The results indicate that TRα1 exerts a predominant but not exclusive role in the regulation of positive and negative genes. However, a fraction of the genes analyzed are not or only mildly affected by the total absence of TRs. Furthermore, hypothyroidism has a mild effect on these genes in the absence of TRα1, in agreement with a role of unliganded TRα1 in the effects of hypothyroidism.
Collapse
Affiliation(s)
- Pilar Gil-Ibañez
- Instituto de Investigaciones Biomédicas, Arturo Duperier 4, 28029 Madrid, Spain.
| | | | | |
Collapse
|
37
|
Genome-wide analysis of thyroid hormone receptors shared and specific functions in neural cells. Proc Natl Acad Sci U S A 2013; 110:E766-75. [PMID: 23382204 DOI: 10.1073/pnas.1210626110] [Citation(s) in RCA: 97] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
TRα1 and TRβ1, the two main thyroid hormone receptors in mammals, are transcription factors that share similar properties. However, their respective functions are very different. This functional divergence might be explained in two ways: it can reflect different expression patterns or result from different intrinsic properties of the receptors. We tested this second hypothesis by comparing the repertoires of 3,3',5-triiodo-L-thyronine (T3)-responsive genes of two neural cell lines, expressing either TRα1 or TRβ1. Using transcriptome analysis, we found that a substantial fraction of the T3 target genes display a marked preference for one of the two receptors. So when placed alone in identical situations, the two receptors have different repertoires of target genes. Chromatin occupancy analysis, performed at a genome-wide scale, revealed that TRα1 and TRβ1 cistromes were also different. However, receptor-selective regulation of T3 target genes did not result from receptor-selective chromatin occupancy of their promoter regions. We conclude that modification of TRα1 and TRβ1 intrinsic properties contributes in a large part to the divergent evolution of the receptors' function, at least during neurodevelopment.
Collapse
|
38
|
Lin JZ, Sieglaff DH, Yuan C, Su J, Arumanayagam AS, Firouzbakht S, Cantu Pompa JJ, Reynolds FD, Zhou X, Cvoro A, Webb P. Gene specific actions of thyroid hormone receptor subtypes. PLoS One 2013; 8:e52407. [PMID: 23300972 PMCID: PMC3536777 DOI: 10.1371/journal.pone.0052407] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2012] [Accepted: 11/14/2012] [Indexed: 11/22/2022] Open
Abstract
There are two homologous thyroid hormone (TH) receptors (TRs α and β), which are members of the nuclear hormone receptor (NR) family. While TRs regulate different processes in vivo and other highly related NRs regulate distinct gene sets, initial studies of TR action revealed near complete overlaps in their actions at the level of individual genes. Here, we assessed the extent that TRα and TRβ differ in target gene regulation by comparing effects of equal levels of stably expressed exogenous TRs +/− T3 in two cell backgrounds (HepG2 and HeLa). We find that hundreds of genes respond to T3 or to unliganded TRs in both cell types, but were not able to detect verifiable examples of completely TR subtype-specific gene regulation. TR actions are, however, far from identical and we detect TR subtype-specific effects on global T3 response kinetics in HepG2 cells and many examples of TR subtype specificity at the level of individual genes, including effects on magnitude of response to TR +/− T3, TR regulation patterns and T3 dose response. Cycloheximide (CHX) treatment confirms that at least some differential effects involve verifiable direct TR target genes. TR subtype/gene-specific effects emerge in the context of widespread variation in target gene response and we suggest that gene-selective effects on mechanism of TR action highlight differences in TR subtype function that emerge in the environment of specific genes. We propose that differential TR actions could influence physiologic and pharmacologic responses to THs and selective TR modulators (STRMs).
Collapse
Affiliation(s)
- Jean Z. Lin
- Genomic Medicine, The Methodist Hospital Research Institute, Houston, Texas, United States of America
- Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, Texas, United States of America
| | - Douglas H. Sieglaff
- Genomic Medicine, The Methodist Hospital Research Institute, Houston, Texas, United States of America
| | - Chaoshen Yuan
- Diabetes Center, University of California Medical Center, San Francisco, California, United States of America
| | - Jing Su
- Radiology Department, The Methodist Hospital Research Institute, Houston, Texas, United States of America
| | | | - Sharareh Firouzbakht
- Genomic Medicine, The Methodist Hospital Research Institute, Houston, Texas, United States of America
| | - Jaime J. Cantu Pompa
- Genomic Medicine, The Methodist Hospital Research Institute, Houston, Texas, United States of America
- Department of Research and Innovation, Tec de Monterrey School of Medicine and Health Science, Monterrey, Mexico
| | - Frances Denoto Reynolds
- Diabetes Center, University of California Medical Center, San Francisco, California, United States of America
| | - Xiabo Zhou
- Radiology Department, The Methodist Hospital Research Institute, Houston, Texas, United States of America
| | - Aleksandra Cvoro
- Genomic Medicine, The Methodist Hospital Research Institute, Houston, Texas, United States of America
| | - Paul Webb
- Genomic Medicine, The Methodist Hospital Research Institute, Houston, Texas, United States of America
- * E-mail:
| |
Collapse
|
39
|
Abstract
Our understanding of thyroid hormone action has been substantially altered by recent clinical observations of thyroid signaling defects in syndromes of hormone resistance and in a broad range of conditions, including profound mental retardation, obesity, metabolic disorders, and a number of cancers. The mechanism of thyroid hormone action has been informed by these clinical observations as well as by animal models and has influenced the way we view the role of local ligand availability; tissue and cell-specific thyroid hormone transporters, corepressors, and coactivators; thyroid hormone receptor (TR) isoform-specific action; and cross-talk in metabolic regulation and neural development. In some cases, our new understanding has already been translated into therapeutic strategies, especially for treating hyperlipidemia and obesity, and other drugs are in development to treat cardiac disease and cancer and to improve cognitive function.
Collapse
Affiliation(s)
- Gregory A Brent
- Department of Medicine, VA Greater Los Angeles Healthcare System, David Geffen School of Medicine at UCLA, Los Angeles, CA 90073, USA.
| |
Collapse
|
40
|
Thyroid hormone receptors: the challenge of elucidating isotype-specific functions and cell-specific response. Biochim Biophys Acta Gen Subj 2012; 1830:3900-7. [PMID: 22704954 DOI: 10.1016/j.bbagen.2012.06.003] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2012] [Revised: 06/04/2012] [Accepted: 06/05/2012] [Indexed: 02/06/2023]
Abstract
BACKGROUND Thyroid hormone receptors TRα1, TRβ1 and TRβ2 are broadly expressed and exert a pleiotropic influence on many developmental and homeostatic processes. Extensive genetic studies in mice precisely defined their respective function. SCOPE OF REVIEW The purpose of the review is to discuss two puzzling issues: MAJOR CONCLUSIONS Mouse genetics support a balanced contribution of expression pattern and receptor intrinsic properties in defining the receptor respective functions. The molecular mechanisms sustaining cell specific response remain hypothetical and based on studies performed with other nuclear receptors. GENERAL SIGNIFICANCE The isoform-specificity and cell-specificity questions have many implications for clinical research, drug development, and endocrine disruptor studies. This article is part of a Special Issue entitled Thyroid hormone signalling.
Collapse
|
41
|
Hwang JY, Attia RR, Zhu F, Yang L, Lemoff A, Jeffries C, Connelly MC, Guy RK. Synthesis and evaluation of sulfonylnitrophenylthiazoles (SNPTs) as thyroid hormone receptor-coactivator interaction inhibitors. J Med Chem 2012; 55:2301-10. [PMID: 22324546 DOI: 10.1021/jm201546m] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
We previously identified a series of methylsulfonylnitrobenzoates (MSNBs) that block the interaction of the thyroid hormone receptor with its coactivators. MSNBs inhibit coactivator binding through irreversible modification of cysteine 298 of the thyroid hormone receptor (TR). Although MSNBs have better pharmacological features than our first generation inhibitors (β-aminoketones), they contain a potentially unstable ester linkage. Here we report the bioisosteric replacement of the ester linkage with a thiazole moiety, yielding sulfonylnitrophenylthiazoles (SNPTs). An array of SNPTs representing optimal side chains from the MSNB series was constructed using parallel chemistry and evaluated to test their antagonism of the TR-coactivator interaction. Selected active compounds were evaluated in secondary confirmatory assays including regulation of thyroid response element driven transcription in reporter constructs and native genes. In addition the selected SNPTs were shown to be selective for TR relative to other nuclear hormone receptors (NRs).
Collapse
Affiliation(s)
- Jong Yeon Hwang
- Medicinal Chemistry Group, Institut Pasteur Korea, 696 Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-400, Korea
| | | | | | | | | | | | | | | |
Collapse
|